[
  "3 DMU/theophylline",
  "5-hydroxyomeprazole",
  "Absence",
  "Acute",
  "Bone",
  "CL & AUC/CL ratio)",
  "Cmax and Tmax)",
  "Cmax and half-life time of fluvoxamine",
  "Dilated",
  "Disease:Abortion",
  "Disease:Acquired Long QT Syndrome (aLQTS)",
  "Disease:Acute cellular rejection",
  "Disease:Acute coronary syndrome",
  "Disease:Adenoma",
  "Disease:Agranulocytosis",
  "Disease:Alcohol abuse",
  "Disease:Alcohol-Related Disorders",
  "Disease:Alopecia",
  "Disease:Alzheimer Disease",
  "Disease:Anemia",
  "Disease:Anxiety Disorders",
  "Disease:Aspirin-induced asthma",
  "Disease:Asthenia",
  "Disease:Asthma",
  "Disease:Atrial Fibrillation",
  "Disease:Attention Deficit Disorder with Hyperactivity",
  "Disease:Autoimmune hepatitis",
  "Disease:Bilateral breast carcinoma",
  "Disease:Bipolar Disorder",
  "Disease:Bradycardia",
  "Disease:Brain Diseases",
  "Disease:Brain Neoplasms",
  "Disease:Breast Neoplasms",
  "Disease:Breast tenderness",
  "Disease:Carcinoma",
  "Disease:Cardiac rhythm disease",
  "Disease:Cardiomyopathies",
  "Disease:Cardiotoxicity",
  "Disease:Cardiovascular Disease",
  "Disease:Central Core Myopathy",
  "Disease:Central Nervous System Disorder",
  "Disease:Chronic Kidney Failure",
  "Disease:Chronic Obstructive Pulmonary Disease",
  "Disease:Cocaine dependence",
  "Disease:Colonic Neoplasms",
  "Disease:Colorectal Neoplasms",
  "Disease:Congenital Heart Defects",
  "Disease:Constipation",
  "Disease:Coronary Artery Disease",
  "Disease:Coronary Disease",
  "Disease:Cough",
  "Disease:Crohn Disease",
  "Disease:Cryptorchidism",
  "Disease:Cystic fibrosis pulmonary exacerbation",
  "Disease:Cystitis",
  "Disease:Death",
  "Disease:Dehydration",
  "Disease:Depression",
  "Disease:Dermatitis",
  "Disease:Diabetes",
  "Disease:Diabetes Mellitus",
  "Disease:Diarrhea",
  "Disease:Disorder of facial skeleton",
  "Disease:Dizziness",
  "Disease:Drug Hypersensitivity",
  "Disease:Drug Reaction with Eosinophilia and Systemic Symptoms",
  "Disease:Drug Resistance",
  "Disease:Drug Toxicity",
  "Disease:Drug-induced liver injury",
  "Disease:Dry mouth",
  "Disease:Dyskinesias",
  "Disease:Edema",
  "Disease:Endometrial Neoplasms",
  "Disease:Epilepsy",
  "Disease:Essential Tremor",
  "Disease:Exanthema",
  "Disease:Fatigue",
  "Disease:Fatty liver disease",
  "Disease:Fever",
  "Disease:Fractures",
  "Disease:Gastric pH",
  "Disease:Gastrointestinal Hemorrhage",
  "Disease:Gastrointestinal toxicity",
  "Disease:Gingival Hyperplasia",
  "Disease:Graft vs Host Disease",
  "Disease:Hallucinations",
  "Disease:Hand-foot syndrome",
  "Disease:Headache",
  "Disease:Headache Disorders",
  "Disease:Heart Failure",
  "Disease:Hematologic Disorder",
  "Disease:Hemolysis",
  "Disease:Hemolytic Anemia",
  "Disease:Hemorrhage",
  "Disease:Hepatic Veno-Occlusive Disease",
  "Disease:Hepatitis",
  "Disease:Hepatitis C virus infection",
  "Disease:Heroin Dependence",
  "Disease:Hot Flashes",
  "Disease:Hyperammonemia",
  "Disease:Hyperbilirubinemia",
  "Disease:Hypercholesterolemia",
  "Disease:Hyperglycemia",
  "Disease:Hyperlipidemias",
  "Disease:Hyperprolactinemia",
  "Disease:Hypersensitivity",
  "Disease:Hypertension",
  "Disease:Hypertriglyceridemia",
  "Disease:Hypoglycemia",
  "Disease:Hypokalemia",
  "Disease:Hypotensive disorder",
  "Disease:Inborn disorder of purine or pyrimidine metabolism",
  "Disease:Infectious disease",
  "Disease:Inflammation",
  "Disease:Insensitivity to pain",
  "Disease:Insulin Resistance",
  "Disease:Interstitial Lung Diseases",
  "Disease:Iron Overload",
  "Disease:Ischemia",
  "Disease:Jaundice",
  "Disease:Kidney Disorder",
  "Disease:Kidney Failure",
  "Disease:King-Denborough syndrome",
  "Disease:Leukemia",
  "Disease:Leukopenia",
  "Disease:Liver Failure",
  "Disease:Lung Neoplasms",
  "Disease:Lymphopenia",
  "Disease:Maculopapular Exanthema",
  "Disease:Major Depressive Disorder",
  "Disease:Malignant Hyperthermia",
  "Disease:Metabolic Bone Disorder",
  "Disease:Metabolic Syndrome",
  "Disease:Methamphetamine dependence",
  "Disease:Methemoglobinemia",
  "Disease:Mucositis",
  "Disease:Multiple Sclerosis",
  "Disease:Muscular Diseases",
  "Disease:Musculoskeletal pain",
  "Disease:Myalgia",
  "Disease:Myelosuppression",
  "Disease:Myocardial Infarction",
  "Disease:Nausea",
  "Disease:Neoplasms",
  "Disease:Nephrolithiasis",
  "Disease:Nephrotoxicity",
  "Disease:Neural Tube Defects",
  "Disease:Neurotoxicity Syndromes",
  "Disease:Neutropenia",
  "Disease:Obesity",
  "Disease:Oligospermia",
  "Disease:Opioid-Related Disorders",
  "Disease:Orthostatic Hypotension",
  "Disease:Osteonecrosis",
  "Disease:Osteoporosis",
  "Disease:Ototoxicity",
  "Disease:Ovarian Neoplasms",
  "Disease:Overall survival",
  "Disease:Pain",
  "Disease:Pancreatitis",
  "Disease:Parkinson Disease",
  "Disease:Parkinsonian Disorder",
  "Disease:Peptic Ulcer Disease",
  "Disease:Peptic Ulcer Hemorrhage",
  "Disease:Peripheral Nervous System Diseases",
  "Disease:Peripheral Vascular Diseases",
  "Disease:Pharyngitis",
  "Disease:Pneumonitis",
  "Disease:Poisoning",
  "Disease:Postoperative Nausea and Vomiting",
  "Disease:Progression-free survival",
  "Disease:Prostatic Neoplasms",
  "Disease:Proteinuria",
  "Disease:Psychotic Disorder",
  "Disease:Recurrence",
  "Disease:Respiratory Insufficiency",
  "Disease:Respiratory Tract Infections",
  "Disease:Rhabdomyolysis",
  "Disease:Rheumatoid arthritis",
  "Disease:Schizophrenia",
  "Disease:Seizures",
  "Disease:Serotonin Syndrome",
  "Disease:Severe Cutaneous Adverse Reactions",
  "Disease:Sickle cell pain crisis",
  "Disease:Skin Neoplasms",
  "Disease:Sleep Disorders",
  "Disease:Stevens-Johnson Syndrome",
  "Disease:Stomatitis",
  "Disease:Stroke",
  "Disease:Substance Withdrawal Syndrome",
  "Disease:Substance-Related Disorders",
  "Disease:Sudden Infant Death",
  "Disease:Suicide",
  "Disease:Syncope",
  "Disease:Tardive Dyskinesia",
  "Disease:Therapy-related acute myeloid leukemia (t-AML)",
  "Disease:Thrombocytopenia",
  "Disease:Thrombotic disease",
  "Disease:Tobacco Use Disorder",
  "Disease:Torsades de Pointes",
  "Disease:Toxic Epidermal Necrolysis",
  "Disease:Toxic liver disease",
  "Disease:Transplant rejection",
  "Disease:Treatment failure",
  "Disease:Urinary Bladder Neoplasms",
  "Disease:Urologic Neoplasms",
  "Disease:Urticaria",
  "Disease:Vaginal dryness",
  "Disease:Venous Thrombosis",
  "Disease:Venous thromboembolism",
  "Disease:Ventricular Fibrillation",
  "Disease:Virus Diseases",
  "Disease:Vomiting",
  "Disease:Weight gain",
  "Disease:adverse cardiovascular events",
  "Disease:delayed graft function",
  "Disease:event-free survival",
  "Disease:interstitial fibrosis",
  "Disease:malaise",
  "Disease:platelet aggregation",
  "Dosage",
  "Drug-Induced",
  "Efficacy",
  "Efficacy: ADP-induced on treatment platelet aggregation (OTPR)",
  "Efficacy: INR >3 (over-anticoagulation)",
  "Efficacy: VASP index",
  "Efficacy: aspirin-resistant phenotype",
  "Efficacy: disease activity as assessed by the physician",
  "Efficacy: on-treatment ADP-induced platelet aggregation",
  "Efficacy: rate of high on-treatment platelet reactivity (HTPR) at 1 month of treatment",
  "Efficacy: rate of hyper-response at 1 month of treatment",
  "Efficacy:24-h excretion of calcium and decreased urinary volume",
  "Efficacy:24-h excretion of chloride and potassium",
  "Efficacy:3 year event free survival",
  "Efficacy:3-year Event Free Survival",
  "Efficacy:5 year survival",
  "Efficacy:8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR)",
  "Efficacy:ADP-induced maximum platelet aggregation",
  "Efficacy:ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention",
  "Efficacy:ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing percutaneous coronary intervention",
  "Efficacy:ADP-induced platelet aggregation",
  "Efficacy:ADP-induced platelet aggregation (PA)",
  "Efficacy:Acute cellular rejection",
  "Efficacy:Acute lymphoblastic leukemia",
  "Efficacy:Alcohol abuse",
  "Efficacy:Angina Pectoris",
  "Efficacy:Anxiety Disorders",
  "Efficacy:Bispectral Index and Ramsay Sedation Scores",
  "Efficacy:Bone Mineral Density",
  "Efficacy:Breast Neoplasms",
  "Efficacy:Bronchopulmonary dysplasia",
  "Efficacy:CD4 T cell count",
  "Efficacy:CNS relapse",
  "Efficacy:Cardiovascular Disease",
  "Efficacy:Cocaine dependence",
  "Efficacy:Complete Remission",
  "Efficacy:Coronary Artery Disease",
  "Efficacy:Coronary Disease",
  "Efficacy:Coronary Restenosis",
  "Efficacy:Craving",
  "Efficacy:Cryoglobulinemia",
  "Efficacy:Death",
  "Efficacy:Decreased glomerular filtration rate",
  "Efficacy:Depression",
  "Efficacy:Discontinuation",
  "Efficacy:Disease Activity",
  "Efficacy:Disease Progression",
  "Efficacy:Disease activity score 28 in rheumatoid arthritis",
  "Efficacy:Drug Resistance",
  "Efficacy:Elevated diastolic blood pressure",
  "Efficacy:Elevated sweat chloride",
  "Efficacy:Elevated systolic blood pressure",
  "Efficacy:Emergencies",
  "Efficacy:Event-Free Survival",
  "Efficacy:Exocrine Pancreatic Insufficiency",
  "Efficacy:FEV1 response",
  "Efficacy:FEV1/FVC ratio",
  "Efficacy:Graft vs Host Disease",
  "Efficacy:HAM-D score changes in fluvoxamine-treated patients compared to paroxetine-treated patients",
  "Efficacy:HAMD scores",
  "Efficacy:HDL-cholesterol",
  "Efficacy:HIV-1 RNA copies below 50 copies/mL or below 200 copies/mL at 48 weeks",
  "Efficacy:Heart Failure",
  "Efficacy:Heart transplantation",
  "Efficacy:High on-treatment platelet reactivity",
  "Efficacy:Hyperbilirubinemia",
  "Efficacy:Hypercholesterolemia",
  "Efficacy:Hyperlipidemias",
  "Efficacy:Hypertension",
  "Efficacy:IC-50",
  "Efficacy:Iron Overload",
  "Efficacy:Kidney Disorder",
  "Efficacy:Kidney Tubular Necrosis",
  "Efficacy:LDL-C reduction",
  "Efficacy:LDL-C response",
  "Efficacy:LDL-C response and vascular event risk response to statin therapy",
  "Efficacy:Leukocytosis",
  "Efficacy:Major Adverse Cardiac Events (MACE)",
  "Efficacy:Mean spinal bone mineral density changes",
  "Efficacy:Median Overall Survival",
  "Efficacy:Metastatic neoplasm",
  "Efficacy:Myocardial Infarction",
  "Efficacy:Myocardial Ischemia",
  "Efficacy:Nausea",
  "Efficacy:Neuropathic pain",
  "Efficacy:On-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI)",
  "Efficacy:Overall survival",
  "Efficacy:Overall survival (OS) time",
  "Efficacy:PC20",
  "Efficacy:PRU",
  "Efficacy:Pain",
  "Efficacy:Parasitemia",
  "Efficacy:Peripheral Vascular Diseases",
  "Efficacy:Platelet reactivity after 9month of treatment",
  "Efficacy:Postoperative Nausea and Vomiting",
  "Efficacy:Progression-free survival",
  "Efficacy:Recurrence",
  "Efficacy:Recurrence free survival",
  "Efficacy:Renal transplant failure",
  "Efficacy:Rheumatoid Nodule",
  "Efficacy:SVR (sustained virological response)",
  "Efficacy:Sickle cell pain crisis",
  "Efficacy:Smoking Cessation",
  "Efficacy:Status asthmaticus",
  "Efficacy:Stroke",
  "Efficacy:Stroke and cerebrovascular accident unspecified",
  "Efficacy:Substance Withdrawal Syndrome",
  "Efficacy:Sudden cardiac death",
  "Efficacy:Sustained virological response (SVR)",
  "Efficacy:Thromboembolism",
  "Efficacy:Thrombotic disease",
  "Efficacy:Transient Ischemic Attack",
  "Efficacy:Transplant rejection",
  "Efficacy:Treatment failure",
  "Efficacy:Treatment interruption",
  "Efficacy:Treatment modification",
  "Efficacy:Vomiting",
  "Efficacy:a 22% increase in therapeutic warfarin dose requirement after adjustment for clinical and genetic covariates in Hispanic-Americans",
  "Efficacy:a 34% increase in therapeutic warfarin dose requirement while holding clinical and genetic predictors constant in Hispanic-Americans",
  "Efficacy:a decrease in visual analog scale >30mm within 6 hours",
  "Efficacy:a lack of response",
  "Efficacy:a lower risk of time to first INR greater than 3.5",
  "Efficacy:a trend of better treatment response (lower HAMD-17 score) starting at week 4",
  "Efficacy:a trend of non-remission",
  "Efficacy:a trend of treatment response",
  "Efficacy:absolute mean blood pressure",
  "Efficacy:abstinance",
  "Efficacy:abstinence",
  "Efficacy:acenocoumarol dose",
  "Efficacy:achieving SVR in older patients with genotype 1b chronic hepatitis C",
  "Efficacy:achieving a stable dose",
  "Efficacy:acquired resistance",
  "Efficacy:acquired resistance to EGFR inhibitor",
  "Efficacy:acquired resistance to EGFR inhibitors",
  "Efficacy:acute cellular rejection",
  "Efficacy:acute rejection",
  "Efficacy:adverse cardiovascular events",
  "Efficacy:adverse outcome",
  "Efficacy:all cause mortality",
  "Efficacy:allograft clinical outcome",
  "Efficacy:allograft rejection",
  "Efficacy:analgesia from codeine for postpartum pain management",
  "Efficacy:angiographic measurements",
  "Efficacy:anti-IFN-beta antibodies",
  "Efficacy:anti-VEGF injections",
  "Efficacy:anti-inflammatory effects",
  "Efficacy:antibody-dependent cellular cytotoxicity",
  "Efficacy:antidepressant response",
  "Efficacy:antiplatelet effect",
  "Efficacy:antiplatelet effect to a 300 mg clopidogrel loading-dose up to 24 h following intervention",
  "Efficacy:antiplatelet response and reduced clopidogrel active metabolite formation",
  "Efficacy:any anticoagulation response",
  "Efficacy:apolipoprotein A1 and C3",
  "Efficacy:aspirin resistance",
  "Efficacy:aspirin-depressed thrombin generation and prolonged bleeding time after aspirin",
  "Efficacy:asthma exacerbation",
  "Efficacy:asthma exacerbations",
  "Efficacy:attenuated response to escitalopram among patients with major depression",
  "Efficacy:average daily dose during the first period of stability",
  "Efficacy:baseline mean arterial blood pressure",
  "Efficacy:being a good responder",
  "Efficacy:being nonresponders",
  "Efficacy:being overrepresented in non-responder group",
  "Efficacy:being sensitive to caffeine",
  "Efficacy:benefit",
  "Efficacy:beta cell function",
  "Efficacy:beta-blockade effect of propranolol",
  "Efficacy:better clinical response",
  "Efficacy:biological response to clopidogrel",
  "Efficacy:biopsy-proven acute rejection (BPAR) at 12 month post-transplant",
  "Efficacy:blood glucose lowering effect",
  "Efficacy:blood glucose lowering effects",
  "Efficacy:blood pressure (BP) reduction",
  "Efficacy:blood pressure response",
  "Efficacy:blunting of alcohol craving",
  "Efficacy:bone density",
  "Efficacy:bone marrow density in the lumbar spine",
  "Efficacy:bone mineral density",
  "Efficacy:bone mineral density response",
  "Efficacy:brief psychiatric rating scale scores",
  "Efficacy:bronchodilator response (BDR)",
  "Efficacy:bronchodilator response (FEV1)",
  "Efficacy:cardiac events",
  "Efficacy:cardiovascular death",
  "Efficacy:cardiovascular disease events",
  "Efficacy:cardiovascular event occurrence",
  "Efficacy:cardiovascular events",
  "Efficacy:chance of positive response to paclitaxel",
  "Efficacy:chance of response",
  "Efficacy:change in HDL-cholesterol",
  "Efficacy:change in forced expiratory volume in 1 s (FEV1)",
  "Efficacy:change in lipid parameters",
  "Efficacy:change in sweat chloride",
  "Efficacy:change in total cholesterol",
  "Efficacy:changes in FEV1",
  "Efficacy:chemoresistance",
  "Efficacy:cholesterol levels",
  "Efficacy:clinical benefit",
  "Efficacy:clinical outcome",
  "Efficacy:clinical outcomes",
  "Efficacy:clinical response",
  "Efficacy:clopi-H4 concentrations after 300 or 900 mg clopidogrel loading dose",
  "Efficacy:clopi-H4 formation or antiplatelet response after 300 or 900 mg clopidogrel loading dose",
  "Efficacy:clopidogrel active metabolite formation and antiplatelet response after a single dose",
  "Efficacy:clopidogrel inhibition of ADP-induced platelet aggregation",
  "Efficacy:clopidogrel on-treatment platelet reactivity (OPR)",
  "Efficacy:clopidogrel poor response",
  "Efficacy:clopidogrel resistance",
  "Efficacy:clopidogrel response in Chinese patients undergoing percutaneous coronary intervention (PCI)",
  "Efficacy:clopidogrel responsiveness",
  "Efficacy:collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration",
  "Efficacy:complete early virological response",
  "Efficacy:complete endoscopic healing",
  "Efficacy:complete pathologic response",
  "Efficacy:complete remission",
  "Efficacy:complete response",
  "Efficacy:complete response rate",
  "Efficacy:coronary artery lesions",
  "Efficacy:cortisol response",
  "Efficacy:cumulative reduction of ribavirin",
  "Efficacy:cytotoxicity",
  "Efficacy:death",
  "Efficacy:decrease in insulin concentration after dexmedetomidine infusion",
  "Efficacy:decreased chance of achieving 6 month abstinence in the placebo group",
  "Efficacy:decreased warfarin dose and increased risk of over-anticoagulation",
  "Efficacy:delayed graft function",
  "Efficacy:delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5",
  "Efficacy:difference in cinacalcet dosage required for calcium normalization and parathyroid hormone reduction",
  "Efficacy:difference in fasting plasma glucose (before and after drug treatment)",
  "Efficacy:difference in postprandial plasma glucose (before and after drug treatment)",
  "Efficacy:differences at any time point for either the HDRS-17 or the GDS (depression rating scales)",
  "Efficacy:differences in ADP-induced platelet aggregation",
  "Efficacy:differences in MADRS scores or clinical improvement after 4 or 6 weeks of treatment",
  "Efficacy:differences in antiepileptic drugs resistance risk",
  "Efficacy:differences in improvement in morning peak expiratory flow (PEF)",
  "Efficacy:differences in in mean proportional HDRS17 decrease (response)",
  "Efficacy:differences in net change in ADP-induced platelet aggregation after aspirin treatment",
  "Efficacy:differences in pharmacodynamic response",
  "Efficacy:differences in platelet aggregation",
  "Efficacy:differences in platelet inhibition",
  "Efficacy:differences in platelet inhibition 7h after a clopidogrel 600-mg loading dose",
  "Efficacy:differences in platelet reactivity and high on-treatment platelet reactivity",
  "Efficacy:differences in remission",
  "Efficacy:differences in remission or tolerance",
  "Efficacy:differences in remission rate",
  "Efficacy:differences in response",
  "Efficacy:differences in response or remission",
  "Efficacy:differences in response to clopidogrel",
  "Efficacy:differences in the trough rosiglitazone steadystate concentrations or in the absolute decrease in HbA1c",
  "Efficacy:differences in therapeutic response or development of nausea",
  "Efficacy:differences in treatment response",
  "Efficacy:differences in treatment response or scores on the various subscales of the PANSS",
  "Efficacy:disease activity as assessed by the physician",
  "Efficacy:disease control rate and lower overall survival rate",
  "Efficacy:disease free survival",
  "Efficacy:disease progression",
  "Efficacy:disease progression or regression",
  "Efficacy:diuretic unresponsiveness",
  "Efficacy:dosage requirement",
  "Efficacy:dose",
  "Efficacy:dose requirement",
  "Efficacy:dose-adjusted tacrolimus blood concentration",
  "Efficacy:drug resistance",
  "Efficacy:drug response",
  "Efficacy:drug-resistance",
  "Efficacy:drug-resistant phenotype",
  "Efficacy:duration of inhibition of prostanoids",
  "Efficacy:dying",
  "Efficacy:earlier achievement of blood pressure control",
  "Efficacy:early decrease in the percentage of HAMD scores",
  "Efficacy:efficact as measured by lower pain relief to opioids",
  "Efficacy:efficacy",
  "Efficacy:efficacy as measured by decrease in HbA1c",
  "Efficacy:efficacy as measured by decrease in HbA1c after 6-month treatment",
  "Efficacy:efficacy of pioglitazone",
  "Efficacy:efficacy or toxicity",
  "Efficacy:efficacy to metformin as measured by HbA1c reduction",
  "Efficacy:emerging viral drug resistance",
  "Efficacy:end of treatment abstinence",
  "Efficacy:enhanced response to clopidogrel (as measured by inhibition of ADP-induced platelet aggregation)",
  "Efficacy:erythrocyte sedimentation rate",
  "Efficacy:event free survival",
  "Efficacy:event-free survival",
  "Efficacy:exacerbations",
  "Efficacy:faster viral elimination (early virologic response) at week 2 or week 4 of antiviral treatment in HCV genotype 3 patients",
  "Efficacy:fatal coronary disease or nonfatal myocardial infarction",
  "Efficacy:favorable virologic responses",
  "Efficacy:fibrin clot formation time",
  "Efficacy:frequency (about double) in non-responder patients compared with responder patients (HCV genotype 4)",
  "Efficacy:frequency of patients who received at least the recommended 80% of scheduled ribavirin",
  "Efficacy:frequency of relapse",
  "Efficacy:frequency of remitters",
  "Efficacy:frequency of rescue analgesic administration",
  "Efficacy:glucocorticoid responsiveness",
  "Efficacy:glucose lowering",
  "Efficacy:glucose-lowering effect of metformin",
  "Efficacy:good response to controlled ovarian hyperstimulation",
  "Efficacy:greater platelet inhibition 2 h after a 600-mg dose",
  "Efficacy:greater positive symptom improvement and positive symptom remission",
  "Efficacy:greater reduction in homocysteine",
  "Efficacy:having INR above target range in week 1",
  "Efficacy:heart rate",
  "Efficacy:hematologic relapse",
  "Efficacy:high on-treatment platelet reactivity",
  "Efficacy:high on-treatment platelet reactivity in CYP2C19*1/*1 carriers",
  "Efficacy:high platelet reactivity",
  "Efficacy:high post-clopidogrel platelet reactivity",
  "Efficacy:high post-treatment platelet reactivity",
  "Efficacy:high-on clopidogrel platelet reactivity",
  "Efficacy:higher P2Y12 reaction units (PRU) and lower percent inhibition",
  "Efficacy:higher fentanyl dose requirement to achieve adequate pain relief in Chinese women undergoing gynecologic surgery",
  "Efficacy:higher mean baseline HCV RNA level and steeper 1st phase HCV RNA decline in genotype 2 and 3 HCV infected patients",
  "Efficacy:higher mean peak INR during week 1 of warfarin therapy",
  "Efficacy:higher platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment",
  "Efficacy:higher rate of sustained virological response (SVR)",
  "Efficacy:higher responsiveness to opioids and required less analgesic drugs in laboring women",
  "Efficacy:immunological failure",
  "Efficacy:improved asthma control (as measured by decrease in average asthma control score)",
  "Efficacy:improved left ventricular ejection fraction",
  "Efficacy:improved response",
  "Efficacy:improved response (marginally significant)",
  "Efficacy:improved second treatment switch response",
  "Efficacy:improvement based on HAM-D score percentage reduction",
  "Efficacy:improvement based on change of HAM-D score after antidepressant medication",
  "Efficacy:improvement in Anxiety-Depression symptoms",
  "Efficacy:improvement in [DELTA]DAS28 (Disease Activity Score)",
  "Efficacy:improvement in bone mineral density",
  "Efficacy:improvement in left ventricular ejection fraction",
  "Efficacy:improvement in left ventricular function (LVEF)",
  "Efficacy:improvement in left ventricular(LV) remodeling",
  "Efficacy:improvement in left ventricular(LV) remodeling and greater increase in LVEF (left ventricular ejection fraction)",
  "Efficacy:improvement of depression symptoms",
  "Efficacy:improvement over the first 2 weeks",
  "Efficacy:improvements in neurovegetative symptoms",
  "Efficacy:in the disease activity score",
  "Efficacy:inadequate inhibition of platelet activity",
  "Efficacy:increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy)",
  "Efficacy:increased risk of being nonresponders",
  "Efficacy:increased risk of nonresponse to methadone maintenance treatment",
  "Efficacy:induction failure",
  "Efficacy:influence on differential bronchodilator effects",
  "Efficacy:inhibition of ADP-induced platelet aggregation",
  "Efficacy:inhibition of FXIII activation by aspirin",
  "Efficacy:inhibition of platelet aggregation and poor-responder status",
  "Efficacy:inhibitory effect on cyclooxygenase 1 activity",
  "Efficacy:insufficient antiplatelet response to clopidogrel",
  "Efficacy:international normalized ratio variability (inr-var)",
  "Efficacy:intolerance to codeine ( significant side effects as well as no pain relief)",
  "Efficacy:intolerance to oxycodone and tramadol ( significant side effects as well as no pain relief)",
  "Efficacy:intoxication",
  "Efficacy:isoproterenol-mediated desensitization in the vasculature",
  "Efficacy:lack of remission and lack of response",
  "Efficacy:lack of response",
  "Efficacy:lack of treatment response",
  "Efficacy:larger mean changes in systolic and diastolic blood pressure",
  "Efficacy:less decrease in the platelet reactivity after 600 mg of clopidogrel",
  "Efficacy:less effective platelet inhibition by aspirin",
  "Efficacy:less pain control in Japanese patients undergoing painful orofacial cosmetic surgery",
  "Efficacy:less robust treatment response",
  "Efficacy:likelihood of severe over-anticoagulation or stability of anticoagulation during long-term therapy",
  "Efficacy:lipid response",
  "Efficacy:lipid-lowering effect",
  "Efficacy:longer median progression-free survival time",
  "Efficacy:low on-treatment platelet reactivity",
  "Efficacy:low-density lipoprotein cholesterol level in basal state and possibly in response to atorvastatin.",
  "Efficacy:lower levels of transthyretin precuror",
  "Efficacy:lower warfarin dose requirement",
  "Efficacy:lumbar spine Bone Mineral Density",
  "Efficacy:lymph node metastases",
  "Efficacy:magnitude of platelet reactivity",
  "Efficacy:maximal platelet aggregation",
  "Efficacy:maximum platelet aggregation (MPA) or the anti-platelet effect of clopidogrel in Chinese stroke patients",
  "Efficacy:mean AUC (area under curve) prothrombin time",
  "Efficacy:mean INR during 3-month daily observation period in patients with mechanical heart valve replacement",
  "Efficacy:mean INR value",
  "Efficacy:mean INR values in patients with heart valve replacement",
  "Efficacy:mean absolute difference in HbA1c",
  "Efficacy:mean annual change in FEV",
  "Efficacy:mean change in FEV",
  "Efficacy:mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine",
  "Efficacy:mean peak INR during week 1 of warfarin therapy",
  "Efficacy:mean percentage reduction of triglycerides level",
  "Efficacy:median survial time",
  "Efficacy:median survival time",
  "Efficacy:median survival time (MST)",
  "Efficacy:median weekly warfarin dose requirements",
  "Efficacy:metabolism and decreased response to tramadol",
  "Efficacy:metabolism of tramadol and decreased response to tramadol",
  "Efficacy:minimal residual disease",
  "Efficacy:more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation",
  "Efficacy:more rapid thrombin generation (P=0.005)",
  "Efficacy:morning peak expiratory flow rate during treatment with regularly scheduled albuterol compared with placebo",
  "Efficacy:mortality",
  "Efficacy:naltrexone-induced blunting of alcohol stimulation and alcohol craving",
  "Efficacy:net decrease in AA-induced platelet aggregation after aspirin treatment",
  "Efficacy:non-remission",
  "Efficacy:non-response",
  "Efficacy:non-response and required higher dose",
  "Efficacy:non-response to aspirin",
  "Efficacy:non-response to clopidogrel",
  "Efficacy:non-response to methotrexate",
  "Efficacy:non-responsiveness",
  "Efficacy:nonresponse to anti-EGFR-based treatment",
  "Efficacy:nonresponse to methadone maintenance treatment",
  "Efficacy:number of examinations above the therapeutic range during 3-month daily observation period in patients with mechanical heart valve replacement",
  "Efficacy:number of failed medication trails",
  "Efficacy:number of seizures per year",
  "Efficacy:numerical rating scale (NRS) score for pain during painful procedure",
  "Efficacy:occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy",
  "Efficacy:on-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI)",
  "Efficacy:on-clopidogrel platelet reactivity (HPR)",
  "Efficacy:on-clopidogrel platelet reactivity (PR) at 1 month and at 6 months after percutaneous coronary intervention (PCI)",
  "Efficacy:on-treatment ADP-induced platelet aggregation",
  "Efficacy:on-treatment platelet activity",
  "Efficacy:on-treatment platelet aggregation",
  "Efficacy:on-treatment platelet reactivity",
  "Efficacy:one year progression free survival",
  "Efficacy:opioids response",
  "Efficacy:or decreased recurrence-free survival time",
  "Efficacy:over-anticoagulation",
  "Efficacy:overall mean numerical rating scale (NRS) score for pain",
  "Efficacy:overall survival",
  "Efficacy:overall survival (OS) time",
  "Efficacy:overall survival and progression-free survival",
  "Efficacy:overall survival and time-to-treat failure",
  "Efficacy:overall survival probability",
  "Efficacy:oxycodone pharmacodynamics (pain intensities",
  "Efficacy:pain relief",
  "Efficacy:pain threshold and pain tolerance",
  "Efficacy:pain tolerance in cold pressor test",
  "Efficacy:peak cortisol response",
  "Efficacy:percent change in FEV",
  "Efficacy:percent reduction in LDL-cholesterol",
  "Efficacy:percentage change in HDL-C levels",
  "Efficacy:percentage change in LDL-cholesterol levels",
  "Efficacy:percentage inhibition of ADP-induced platelet aggregation",
  "Efficacy:permanent early discontinuation",
  "Efficacy:persistent response",
  "Efficacy:pharmacodynamic response",
  "Efficacy:pharmacological resistance",
  "Efficacy:phase 1 or phase 2 viral decay",
  "Efficacy:physical and life well-being quality of life (QoL) scales",
  "Efficacy:platelet activation response to ADP",
  "Efficacy:platelet aggregation",
  "Efficacy:platelet aggregation activity as measured by the VerifyNow P2Y12 test",
  "Efficacy:platelet aggregation after stimuli with adenosine diphosphate",
  "Efficacy:platelet aggregation inhibition",
  "Efficacy:platelet aggregation values",
  "Efficacy:platelet inhibition",
  "Efficacy:platelet inhibition 7h after a clopidogrel 600-mg loading dose",
  "Efficacy:platelet inhibition after a clopidogrel 600-mg loading dose",
  "Efficacy:platelet inhibition by aspirin",
  "Efficacy:platelet reactivity",
  "Efficacy:platelet reactivity after 9month of treatment",
  "Efficacy:platelet reactivity index (PRI) at 4 h after the dosing",
  "Efficacy:platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment",
  "Efficacy:platelet responsiveness to clopidogrel",
  "Efficacy:poor response",
  "Efficacy:poor response after 8 weeks of treatment",
  "Efficacy:poor response at 6 week of treatment",
  "Efficacy:poor response at 8 week of treatment",
  "Efficacy:poor-response to clopidogrel",
  "Efficacy:poorer reduction in low-density lipoprotein cholesterol (LDLc)",
  "Efficacy:positive correlation of paroxetine concentration with improvement in HAMD scores at week 2",
  "Efficacy:positive relationship between olanzapine plasma levels and positive symptom reduction compared to subjects with the GG genotype",
  "Efficacy:positive response",
  "Efficacy:post-HbA1c levels",
  "Efficacy:post-treatment ADP-stimulated platelet aggregation",
  "Efficacy:presentation in the non-reponder group",
  "Efficacy:primary graft failure",
  "Efficacy:primary outcome",
  "Efficacy:primary outcome (all cause mortality",
  "Efficacy:probability of antiepileptic drug response",
  "Efficacy:prognosis",
  "Efficacy:progression free survival",
  "Efficacy:progression free survival (PFS) time",
  "Efficacy:progression-free survival",
  "Efficacy:progression-free survival (PFS) (P=0.00004) and overall survival (OS) (P=0.034)",
  "Efficacy:progression-free survival (PFS) time",
  "Efficacy:progression-free survival or overall survival",
  "Efficacy:propertion of the first 6 months' treatment time spent within the target INR range (PTIR)",
  "Efficacy:prophylactic treatment response",
  "Efficacy:prostate cancer-specific mortality",
  "Efficacy:protection against myocardial infarction",
  "Efficacy:protection from drug resistance",
  "Efficacy:prothrombin time (PT) at induction",
  "Efficacy:rapid viral response (RVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients",
  "Efficacy:rapid virological response (RVR) in HCV-HIV coinfected patients",
  "Efficacy:rapid virological response (rvr)",
  "Efficacy:rate of acute rejection",
  "Efficacy:rates of target lesion revascularization and major adverse cardiovascular events",
  "Efficacy:reaching target cholesterol levels",
  "Efficacy:reaction time",
  "Efficacy:recurrence",
  "Efficacy:recurrence of acute coronary events",
  "Efficacy:recurrence of breast cancer",
  "Efficacy:recurrence of disease",
  "Efficacy:recurrence-free survival",
  "Efficacy:reduced GP IIb/IIIa activation and lower platelet activation",
  "Efficacy:reduced progression-free survival",
  "Efficacy:reduced response",
  "Efficacy:reduced warfarin dose in African Americans",
  "Efficacy:reduction in C-reactive protein (CRP)",
  "Efficacy:reduction in COX-1 inhibition",
  "Efficacy:reduction in COX-1 inhibition and depression of the urinary thromboxane metabolite",
  "Efficacy:reduction in CRP levels",
  "Efficacy:reduction in D-dimer levels",
  "Efficacy:reduction in DNA damage",
  "Efficacy:reduction in HbA1c levels",
  "Efficacy:reduction in IL-6 levels",
  "Efficacy:reduction in LDL",
  "Efficacy:reduction in LDL-C",
  "Efficacy:reduction in LDLc",
  "Efficacy:reduction in OTR",
  "Efficacy:reduction in SBP",
  "Efficacy:reduction in ambulatory SBP",
  "Efficacy:reduction in ambulatory blood pressure",
  "Efficacy:reduction in blood pressure",
  "Efficacy:reduction in diastolic blood pressure",
  "Efficacy:reduction in fasting IL-2",
  "Efficacy:reduction in fasting LDL-C",
  "Efficacy:reduction in low-density lipoprotein cholesterol (LDL-C) level",
  "Efficacy:reduction in luminal diameter",
  "Efficacy:reduction in mean arterial pressure",
  "Efficacy:reduction in mean blood pressure",
  "Efficacy:reduction in office diastolic blood pressure",
  "Efficacy:reduction in pain",
  "Efficacy:reduction in pain AUC",
  "Efficacy:reduction in psychotic symptoms",
  "Efficacy:reduction in resting blood pressure",
  "Efficacy:reduction in systolic blood pressure",
  "Efficacy:reduction in total cholesterol",
  "Efficacy:reduction in total cholesterol and LDL-cholesterol",
  "Efficacy:reduction in whole day ambulatory blood pressure",
  "Efficacy:reduction of LDL cholesterol",
  "Efficacy:rejection or affect graft function by 1 year after transplantation",
  "Efficacy:relapse",
  "Efficacy:relapse free time",
  "Efficacy:relapse in the central nervous system",
  "Efficacy:relative inhibition of ADP-induced platelet aggregation",
  "Efficacy:remission",
  "Efficacy:remission (reported as trend of association)",
  "Efficacy:remission after second treatment switch",
  "Efficacy:remission at 8 weeks",
  "Efficacy:remission if tolerant to citalopram treatment",
  "Efficacy:remission rates",
  "Efficacy:required dose",
  "Efficacy:requiring more heart failure medication",
  "Efficacy:residual on-clopidogrel platelet reactivity",
  "Efficacy:residual platelet aggregation",
  "Efficacy:residual platelet aggregation to collagen and epinephrine",
  "Efficacy:residual platelet reactivity",
  "Efficacy:resistance",
  "Efficacy:resistant hypertension",
  "Efficacy:resistant relapse",
  "Efficacy:response",
  "Efficacy:response (SVR and RVR) in HCV-HIV coinfected patients",
  "Efficacy:response (SVR rate) to HCV triple therapy (telaprevir (TVR)",
  "Efficacy:response (SVR) in HCV genotype 1 patients",
  "Efficacy:response (SVR) in HCV genotype 2 patients",
  "Efficacy:response (SVR) to interferon monotherapy in HCV genotype 1 patients",
  "Efficacy:response (SVR) to interferon monotherapy in HCV genotype 2 patients",
  "Efficacy:response (heart-rate lowering)",
  "Efficacy:response (pain relief) to oxycodone",
  "Efficacy:response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1",
  "Efficacy:response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels)",
  "Efficacy:response and remission rate",
  "Efficacy:response at 4 weeks after the initiation of treatment",
  "Efficacy:response base on Disease Activity Score in 44 joints improvement at 6 months of treatment",
  "Efficacy:response rate",
  "Efficacy:response rate (RR)",
  "Efficacy:response rate after 10 weeks of pioglitazone treatment",
  "Efficacy:response rate or mean change of depressive symptoms",
  "Efficacy:response rate to pegIFN-alpha/RBV treatment at week 20/24",
  "Efficacy:response rates",
  "Efficacy:response time",
  "Efficacy:response to chemotherapy",
  "Efficacy:response to clopidogrel and poorer outcomes in Chinese patients with acute ischemic stroke",
  "Efficacy:response to hydrocodone",
  "Efficacy:response to metformin",
  "Efficacy:response to methotrexate",
  "Efficacy:response to oral hydrocodone",
  "Efficacy:response to propranolol (as measured by percentage reductions in exercise heart rate)",
  "Efficacy:response when measured by the Geriatric Depression Scale at day 7 and day 28",
  "Efficacy:rise in CD4-cell count",
  "Efficacy:risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients",
  "Efficacy:sedation",
  "Efficacy:sen sitivity to warfarin during induction",
  "Efficacy:sensitivity",
  "Efficacy:serum osteocalcin",
  "Efficacy:severe warfarin resistance",
  "Efficacy:shorter time to first therapeutic INR and time to first INR>4",
  "Efficacy:shorter time to have over-anticoagulation (INR >4) risk",
  "Efficacy:shorter time to the first INR of more than 4",
  "Efficacy:significantly delayed time to inhibition of platelet aggregation (IPA)",
  "Efficacy:significantly greater improvement in left ventricular ejection fraction (LVEF)",
  "Efficacy:significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily",
  "Efficacy:slower analgesic onset in European Americans undergoing oral surgery",
  "Efficacy:slower response time",
  "Efficacy:smaller mean changes in systolic and diastolic blood pressure",
  "Efficacy:smoking abstinence within slow nicotine metabolizers",
  "Efficacy:smoking cessation",
  "Efficacy:social and clinical needs",
  "Efficacy:stable warfarin dose univariately",
  "Efficacy:staying in remission",
  "Efficacy:stronger aggreagtion",
  "Efficacy:subclinical intra-stent thrombus",
  "Efficacy:suboptimal reperfusion (post-PCI TIMI flow <3)",
  "Efficacy:success rate in achieving short-term remission",
  "Efficacy:successful rhythm control",
  "Efficacy:survival",
  "Efficacy:survival rate",
  "Efficacy:survival time",
  "Efficacy:sustained virological response (SVR)",
  "Efficacy:sustained virological response (SVR) and changes in viral load after 4 weeks of treatment",
  "Efficacy:sustained virological response (SVR) rate in HCV genotype 3 patients",
  "Efficacy:sustained virological response (SVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients",
  "Efficacy:tendency toward greater improvement in PANSS-T",
  "Efficacy:the antiplatelet effect or clinical outcomes of clopidogrel",
  "Efficacy:the efficacy of ocycodone",
  "Efficacy:the lack of aspirin effect",
  "Efficacy:the lipid-lowering efficacy of pravastatin",
  "Efficacy:the most benefit from statin treatment in reducing the risk of myocardial infarction",
  "Efficacy:the response of total cholesterol",
  "Efficacy:the time to achieve a first INR within the therapeutic range",
  "Efficacy:therapeutic effectiveness or side effects",
  "Efficacy:therapeutic response",
  "Efficacy:therapeutic warfarin dose requirement in African-Americans",
  "Efficacy:therapeutic warfarin dose requirement while holding clinical and genetic predictors constant in African-Americans",
  "Efficacy:time above therapeutic range",
  "Efficacy:time below therapeutic range",
  "Efficacy:time in therapeutic range",
  "Efficacy:time in therapeutic range of INR (TTR)",
  "Efficacy:time to achieve stable dose",
  "Efficacy:time to first therapeutic INR and time to first INR>4",
  "Efficacy:time to improve (based on mean reductions from baseline in HRSD)",
  "Efficacy:time to progression",
  "Efficacy:time to respond",
  "Efficacy:time to the first INR within the therapeutic range",
  "Efficacy:time to therapeutic INR>=2",
  "Efficacy:time to therapeutic inr",
  "Efficacy:time to tumor recurrence",
  "Efficacy:time until response",
  "Efficacy:time-to-tumor recurrence",
  "Efficacy:to be classified as clopidogrel poor responders",
  "Efficacy:tonic block of Na(V) 1.1 channels",
  "Efficacy:total and the low-density lipoprotein cholesterol maximum percent decreases from baseline",
  "Efficacy:tramadol metabolism and response",
  "Efficacy:transplant rejection",
  "Efficacy:treatment duration",
  "Efficacy:treatment emergent mania",
  "Efficacy:treatment failure",
  "Efficacy:treatment failure in Japanese patients with with chronic genotype 1 HCV infection",
  "Efficacy:treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients",
  "Efficacy:treatment inefficacy",
  "Efficacy:treatment outcome",
  "Efficacy:treatment resistance",
  "Efficacy:treatment response",
  "Efficacy:treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype",
  "Efficacy:treatment success on any of the outcome measures",
  "Efficacy:treatment-resistance",
  "Efficacy:trough metformin steady-state concentration",
  "Efficacy:tumor response",
  "Efficacy:tumor response rate",
  "Efficacy:ultra-resistance",
  "Efficacy:uncontrolled asthma",
  "Efficacy:urinary DPD/Cr levels",
  "Efficacy:vasodilator response",
  "Efficacy:virological response",
  "Efficacy:virological response (early",
  "Efficacy:vol% end-tidal sevoflurane concentration",
  "Efficacy:weight loss",
  "Efficacy:worse outcome (overall survival and progression-free survival)",
  "Efficacy:worse prognoses",
  "Efficacy:worse prognosis (overall survival and progression-free survival) in patients who were ER-ve/PR-ve negative",
  "Febrile",
  "Gestational",
  "HDL",
  "HDL and LDL/HDL",
  "LDL",
  "M3G and M6G levels but not those of codeine",
  "MI",
  "Metabolism/PK",
  "Myeloid",
  "Other",
  "Other:20% and 17% less inhibition of platelet aggregation with crangrelor (0.05 and 0.25 microM) in-vitro",
  "Other:5% lower ADP-induced peak platelet aggregation in-vitro",
  "Other:A blood group antigen",
  "Other:ACE activity",
  "Other:ACE insertion",
  "Other:ADP-stimulated platelet aggregation",
  "Other:Acidosis",
  "Other:Adenoma",
  "Other:Alcohol abuse",
  "Other:Apnea",
  "Other:Aspirin-induced asthma",
  "Other:Asthma",
  "Other:Attention Deficit Disorder with Hyperactivity",
  "Other:B blood group antigen",
  "Other:BMD values at the lumbar spine and femoral neck",
  "Other:BMI",
  "Other:Baseline Bone Mineral Density",
  "Other:Blood Coagulation Disorders",
  "Other:Bone Mineral Density",
  "Other:Brain Ischemia",
  "Other:Breast Neoplasms",
  "Other:COVID-19",
  "Other:Cardiac Arrest",
  "Other:Cardiovascular events",
  "Other:Central Core Myopathy",
  "Other:Chronic Kidney Failure",
  "Other:Chronic lung allograft dysfunction",
  "Other:Cocaine dependence",
  "Other:Coronary Artery Disease",
  "Other:Crigler-Najjar Syndrome",
  "Other:Death",
  "Other:Decreased glomerular filtration rate",
  "Other:Dehydration",
  "Other:Diabetes",
  "Other:Diabetes Mellitus",
  "Other:Diabetic Retinopathy",
  "Other:Discontinuation",
  "Other:Disease Free Survival",
  "Other:Disease-Free Survival",
  "Other:Down Syndrome",
  "Other:Drug Toxicity",
  "Other:Elevated circulating creatine kinase concentration",
  "Other:Elevated systolic blood pressure",
  "Other:Emergencies",
  "Other:Euphoric and Energetic after amphetamine (10 mg)",
  "Other:Fever",
  "Other:G6PD Deficiency",
  "Other:Gastric pH",
  "Other:Gilbert syndrome",
  "Other:HDL cholesterol",
  "Other:HLA-B*5701",
  "Other:HMGCRv_1 expression and an increase in the expression of the full-length transcript",
  "Other:Hearing Loss",
  "Other:Helicobacter pylori infection",
  "Other:Heroin Dependence",
  "Other:High Platelet Reactivity",
  "Other:High Platelet Reactivity (HPR)",
  "Other:Hyperbilirubinemia",
  "Other:Hypertriglyceridemia",
  "Other:Hyperuricemia",
  "Other:Hypoglycemia",
  "Other:IL1B serum levels",
  "Other:Inborn disorder of purine or pyrimidine metabolism",
  "Other:Infant",
  "Other:Iron Overload",
  "Other:Jaundice",
  "Other:Kallmann Syndrome",
  "Other:MRdextromethorphane/dextrorphane ratio above 0.3",
  "Other:Malignant Hyperthermia",
  "Other:Manic Symptoms in Psychosis",
  "Other:Marijuana Abuse",
  "Other:Medication adherence",
  "Other:Memory impairment",
  "Other:Metastatic neoplasm",
  "Other:Methamphetamine dependence",
  "Other:Myocardial Infarction",
  "Other:Neonatal Abstinence Syndrome",
  "Other:Neonatal hyperbilirubinemia",
  "Other:Neoplasms",
  "Other:Nephrotoxicity",
  "Other:Non-Small Cell Lung Carcinoma",
  "Other:Opioid-Related Disorders",
  "Other:Osteoarthritis",
  "Other:Overall survival",
  "Other:P2Y12 reaction unit(PRU) values",
  "Other:Pain",
  "Other:Peripheral Vascular Diseases",
  "Other:Physiological sexual disorder",
  "Other:Poisoning",
  "Other:Pre-Eclampsia",
  "Other:Premature Birth",
  "Other:Progression-free survival",
  "Other:QT interval",
  "Other:Recurrence",
  "Other:Recurrence free survival",
  "Other:Recurrent pregnancy loss",
  "Other:Respiratory Insufficiency",
  "Other:Sickle cell pain crisis",
  "Other:Smoking Cessation",
  "Other:Status asthmaticus",
  "Other:Stimulation and Euphoria scores after amphetamine",
  "Other:Stroke",
  "Other:Substance Withdrawal Syndrome",
  "Other:Substance-Related Disorders",
  "Other:TPMT activity",
  "Other:Tobacco Use Disorder",
  "Other:Toxic liver disease",
  "Other:Transplant rejection",
  "Other:Treatment modification",
  "Other:Uremia",
  "Other:Very-long-chain Acyl-coenzyme A Dehydrogenase Deficiency",
  "Other:Vitamin D Deficiency",
  "Other:Vomiting",
  "Other:a 3 SNP combination marker for prognosis",
  "Other:a correlation of brain SERT occupancy was associated with larger proportional HDRS17 decreases",
  "Other:a functional effect on the P-gp-mediated transport rate",
  "Other:a higher accumulation of lopinavir in peripheral blood mononuclear cells",
  "Other:a more rapid attainment of target INR and higher frequency of dose adjustments",
  "Other:absolute leucocyte and neutrophil counts on day 15",
  "Other:abstinence",
  "Other:achieved LDL cholesterol levels",
  "Other:acute kidney injury",
  "Other:acute rejection",
  "Other:addiction",
  "Other:adenomatous and hyperplastic polyps",
  "Other:adenosine-stimulated myocardial flow",
  "Other:adverse cardiovascular events",
  "Other:adverse cardiovascular outcomes",
  "Other:adverse events",
  "Other:affinity of atypical cholinesterase for choline esters",
  "Other:alcohol response",
  "Other:all-cause mortality",
  "Other:allelic imbalence",
  "Other:ambulatory blood pressure",
  "Other:aspirin-intolerant asthma",
  "Other:asthma exacerbations",
  "Other:atopy in patients with aspirin-intolerant chronic urticaria",
  "Other:basal but an increased rifampin-induced transactivation of CYP3A4 promoter reporter gene",
  "Other:basal transactivation of CYP3A4 promoter reporter gene",
  "Other:basal urinary coproporphyrin I/ (I+III) ratio",
  "Other:baseline proinsulin levels after adjusting for insulin levels",
  "Other:baseline viral load",
  "Other:better survival outcome",
  "Other:biochemical response",
  "Other:biopsy-proven acute rejection",
  "Other:blood pressure",
  "Other:bone marrow density in the lumbar spine",
  "Other:bone mineral density",
  "Other:bone mineral density (BMD)",
  "Other:bone mineral density at femoral neck and lumbar spine",
  "Other:cardiac rehospitalization",
  "Other:cardiovascular death",
  "Other:cardiovascular events",
  "Other:change in lipid parameters",
  "Other:cholesterol levels",
  "Other:cholesterol synthesis rate",
  "Other:chronic kidney disease",
  "Other:cigarettes per day",
  "Other:coffee consumption",
  "Other:collagen-induced platelet aggregation",
  "Other:complications",
  "Other:concentrations of S-citalopram and metabolic ratio of of S-desmethylcitalopram/citalopram",
  "Other:coronary flow reserve",
  "Other:cortical silent period duration",
  "Other:craving",
  "Other:creatinine clearance",
  "Other:current smoking",
  "Other:dependence",
  "Other:dexmedetomidine ED50 values for drug-induced dorsal hand vein (DHV) constriction",
  "Other:dextromethorphan (DM):dextrorphan (DX) metabolic ratio after 8 days fluoxetine",
  "Other:dextromethorphan (DM):dextrorphan (DX) metabolic ratio after 8 days paroxetine",
  "Other:differences in carbamazepine disposition",
  "Other:differences in paroxetine daily dose",
  "Other:differences of in-vitro platelet [3H]paroxetine binding",
  "Other:disease recurrence",
  "Other:disease syptoms (such as higher baseline PANSS total score)",
  "Other:disease-free survival and overall survival",
  "Other:dose decrease or drug switching",
  "Other:drug dosage altered",
  "Other:early relapse",
  "Other:emergency department and hospital utliization",
  "Other:emergency department or hospital utliization",
  "Other:emergency department utliization",
  "Other:endogenous levels of EPO",
  "Other:erythrocyte plasma membrane fluidity",
  "Other:erythromycin transport",
  "Other:event-free survival",
  "Other:exposure",
  "Other:expression of enzyme contributing to the metabolism",
  "Other:fasting insulin",
  "Other:functional MRI reactivity to smoking images",
  "Other:functional effect on the P-gp-mediated transport rate",
  "Other:greater heart rate (HR) reduction",
  "Other:habitual consumption",
  "Other:having warfarin Dose greater than 7.5 mg/day",
  "Other:heart rate",
  "Other:heart rate (HR) and diastolic blood pressure (DBP) reductions during early titration",
  "Other:heavy consumption",
  "Other:high on-aspirin residual platelet reactivity",
  "Other:higher average daily dose in patients with hyper- kinetic movement disorders",
  "Other:higher dose of warfarin",
  "Other:higher mean warfarin daily dose requirement",
  "Other:higher stable dose levels",
  "Other:hospital stay",
  "Other:hydrochlorothiazide induced calcium retention",
  "Other:hydrochlorothiazide induced potassium excretion",
  "Other:iNOS expression",
  "Other:in-stent restenosis",
  "Other:increase in MRdextromethorphane/dextrorphane ratio",
  "Other:increase in serum concentrations of dextromethorphan",
  "Other:increased expression of a modified TNFR1 protein with capablility of TNF antagonism",
  "Other:increased soluble gamma-gamma-dimer formation",
  "Other:inhibition of CYP3A-catalyzed metabolism of midazolam or testosterone",
  "Other:inosine monophosphate dehydrogenase activity",
  "Other:intake",
  "Other:intelligence",
  "Other:international normalized ratio variability (inr-var)",
  "Other:interstitial inflammatory cell infiltration",
  "Other:intragastric pH",
  "Other:later onset of sensory neuropathy",
  "Other:length of hospital stay",
  "Other:level of apolipoprotein A1",
  "Other:levels of IgG",
  "Other:levels of vitamin K-dependent proteins",
  "Other:longer titration to achieve optimal benefit",
  "Other:loss of human red blood cells",
  "Other:lumbar spine Bone Mineral Density",
  "Other:lymph node involvement",
  "Other:lymph node metastasis",
  "Other:maintenance dose of warfarin",
  "Other:major adverse cardiac events",
  "Other:major adverse cardiovascular events",
  "Other:meal-stimulated plasma gastrin concentrations",
  "Other:mean arterial pressure",
  "Other:metabolic ratio DEM/DOR",
  "Other:methylation at sites 1 and 2 in the COMT promoter",
  "Other:mortality (due to sepsis or cardiovascular causes)",
  "Other:mortality after myocardial infarction",
  "Other:nephrotoxicity",
  "Other:nicotine dependence",
  "Other:non-fatal myocardial infarction",
  "Other:number of cigarettes smoked per day",
  "Other:opiate withdrawal symptoms",
  "Other:or decreased plasma levels of endoxifen or 4-hydroxytamoxifen in recipients",
  "Other:oroceccal transit time",
  "Other:osteoporotic fracture",
  "Other:outcome time to stable dose",
  "Other:overall or progression-free survival",
  "Other:overall survival",
  "Other:overanticoagulation",
  "Other:overcoming nicotine dependence",
  "Other:oxidative stress",
  "Other:patient stability",
  "Other:peak plasma concentration of increased prolactin",
  "Other:percentage of days abstinent and lower number of drinks per drinking day",
  "Other:plasma concentration of S-didesmethyl-citalopram",
  "Other:plasma level",
  "Other:plasma level of high-sensitivity C-reactive protein",
  "Other:platelet aggregation",
  "Other:platelet aggregation with ADP",
  "Other:platelet aggregation with epinephrine",
  "Other:platelet function",
  "Other:platelet reactivity",
  "Other:platelet reactivity by P2Y12 reaction units",
  "Other:post-traumatic stress disorder (PTSD)",
  "Other:primary outcome",
  "Other:progression-free survival",
  "Other:progression-free survival and overall survival",
  "Other:prolactin",
  "Other:promoter activity in reporter assays and reduced binding to transcription repressor MZF-1",
  "Other:protection against developing severe malaria",
  "Other:protection against severe (p=0.006) and mild malaria (p=0.027)",
  "Other:protection against severe malaria",
  "Other:protection from Plasmodium vivax malaria infection",
  "Other:psychosis",
  "Other:recurrence-free survival",
  "Other:recurrent coronary events",
  "Other:reductions in glutathione levels",
  "Other:remaining on steroids at 1 year after transplantation",
  "Other:requiring postoperative intervention",
  "Other:rotor syndrome",
  "Other:same protective properties against angiotensin-converting enzyme inhibitors-induced cough",
  "Other:sensitive to antilymphocyte serum",
  "Other:sensitivity in vitro",
  "Other:sensitivity to abciximab",
  "Other:sensitivity to aspirin",
  "Other:sensitivity to etoposide",
  "Other:serum LDL",
  "Other:serum and red blood cell folate concentrations",
  "Other:serum total cholesterol",
  "Other:severe exacerbations with asthma",
  "Other:short and long-term weight loss",
  "Other:shorter bleeding time",
  "Other:significantly higher tramadol consumption in Chinese gastric cancer patients recovering from gastrectomy",
  "Other:significantly shorter survival",
  "Other:small-dense LDL levels",
  "Other:smoking",
  "Other:smoking cessation",
  "Other:smoking initiation",
  "Other:smoking quantity",
  "Other:social withdrawal",
  "Other:spine Bone Mineral Density",
  "Other:spontaneous HCV clearance",
  "Other:stable warfarin dose",
  "Other:statin doses for optimal lipid control",
  "Other:stop reaction time",
  "Other:subclinical acute rejection",
  "Other:subclinical allograft nephropathy",
  "Other:subjective feelings of intoxication",
  "Other:suicidal ideation",
  "Other:survival",
  "Other:survival of red blood cells",
  "Other:systolic (SAP) and diastolic (DAP) arterial pressure responses to timolol",
  "Other:tacrolimus nephrotoxicity",
  "Other:tacrolimus-induced toxicity",
  "Other:tamoxifen-induced changes in levels of total cholesterol",
  "Other:the levels of the coagulation or inflammatory biomarkers or serum cardiac biomarker hs-TnT",
  "Other:the levels of the coagulation or inflammatory biomarkers or serum cardiac biomarker hs-TnT in patients undergoing elective percutaneous coronary intervention (PCI)",
  "Other:the short-term effects of statins on cholesterol homeostasis",
  "Other:time between first drug administration and dose reduction or termination of therapy",
  "Other:time to therapeutic inr",
  "Other:time to tumor recurrence (TTR)",
  "Other:total cholesterol",
  "Other:treatment",
  "Other:tubular vacuolar degeneration",
  "Other:tumor size",
  "Other:use",
  "Other:variance in LDL",
  "Other:wakefulness activity level",
  "Other:warfarin dose",
  "Other:warfarin dose (40% lower)",
  "Other:warfarin dose after adjustment for VKORC1*1173",
  "Other:warfarin dose during 3-month daily observation period in patients with mechanical heart valve replacement",
  "Other:warfarin dose in Japanese patients",
  "Other:warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy",
  "Other:warfarin dose in african americans",
  "Other:warfarin dose requirement",
  "Other:warfarin dose requirement in mechanical heart valve replacement patients",
  "Other:warfarin dose requirements on day 14",
  "Other:warfarin sensitivity index",
  "Other:warfarin sensitivity index (INR/Cpss)",
  "Other:warfarin variability",
  "Other:weight",
  "Other:weight regain after intentional weight loss",
  "Other:whole blood nitrite",
  "Other:worse overall survival outcome",
  "PD",
  "PK: apparent terminal elimination half-life",
  "PK: area under the concentration versus time curve (AUC6-12) level of the acyl glucuronide of mycophenolic acid",
  "PK: area under the plasma concentration-time curve",
  "PK: atomoxetine and methylphenidateplasma concentration after overdose",
  "PK: nevirapine AUC0-6 h",
  "PK: plasma paroxetine concentrations at administered dose of 10mg/day",
  "PK: serum R -warfarin concentration",
  "PK: steady-state Cmax and AUC(0-24) and the lowest clearance",
  "PK: venlafaxine Cmax and AUC",
  "PK:(S)-methadone plasma levels",
  "PK:25% higher mean 4'-desmethyl OLA/olanzapine (OLA) ratio",
  "PK:29% lower mean 4'-desmethyl OLA/olanzapine (OLA) ratio",
  "PK:6-MMPN levels",
  "PK:6-TG levels",
  "PK:6-mercaptopurine and methyl-mercaptopurine nucleotide levels",
  "PK:6-thioguanine and 6-thioguanine nucleotide levels",
  "PK:9-hydroxy-risperidone levels",
  "PK:ABT-751 pharmacokinetic parameters",
  "PK:AUC",
  "PK:AUC (p=0.002) and Cmax (p=0.003)",
  "PK:AUC 0-4 hours",
  "PK:AUC and C max of tolterodine and undetectable 5-HMT (active metabolite)",
  "PK:AUC and half-life time (t1/2)",
  "PK:AUC and longer longer flurbiprofen elimination half-life",
  "PK:AUC of celecoxib",
  "PK:AUC of citalopram",
  "PK:AUC of the S-enantiomer of citalopram (no effect on R-CT)",
  "PK:AUC of the sum of doxepin and N-desmethyldoxepin",
  "PK:AUC simvastatin acid",
  "PK:AUC0-12",
  "PK:Bosentan metabolism in vitro",
  "PK:C/D ratio",
  "PK:CL renal reference and lower and CL sec reference",
  "PK:CLrenal nor the secretory clearance (CLsec) of metformin",
  "PK:CYP3A4 acitvity",
  "PK:Cmax and AUC of thiol metabolite",
  "PK:Cmax and AUC of venlafaxine",
  "PK:Cmax and a lower mean AUC",
  "PK:Cmax of the active metabolite",
  "PK:DPD activity",
  "PK:HDL-C concentration",
  "PK:IC50",
  "PK:M-III:pioglitazone AUC0-48 ratio and M-III:M-IV AUC0-48 ratio in healthy African-American volunteers",
  "PK:Mean oxymorphone/oxycodone ratios",
  "PK:Overdose",
  "PK:Oxycodone consumption up to the 12(th) hour in postoperative patients",
  "PK:PBMC concentrations",
  "PK:PBMC-associated drug concentrations",
  "PK:PK",
  "PK:Piroxicam's area under the plasma concentration-time curve and decreased oral clearance",
  "PK:R-ibuprofen metabolism",
  "PK:S-CIT serum concentrations",
  "PK:S-mirtazapine plasma levels in non-smokers at day 14 of treatment",
  "PK:S-norfluoxetine/S-fluoxetine ratios",
  "PK:S-oxazepam glucuronidation in human liver microsomes",
  "PK:S-propranolol plasma concentration",
  "PK:S-warfarin clearance",
  "PK:Serum anticholinergic activity",
  "PK:UGT1A9 activity for propofol",
  "PK:Unbound oral clearance for S-warfarin",
  "PK:Vmax",
  "PK:a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin",
  "PK:a trend towards increased clearance of desipramine",
  "PK:accumulation of drug in PBMCs",
  "PK:achieving optimal trough level",
  "PK:achieving target concentrations",
  "PK:active moiety levels",
  "PK:acute rejection",
  "PK:adjusted trough concentrations",
  "PK:age-related decline in flecainide clearance patients treated with oral flecainide for supraventricular tachyarrhythmias",
  "PK:altered plasma concentrations",
  "PK:amitriptyline + nortriptyline plasma concentration in one CYP2D6 PM",
  "PK:amitriptyline/(E)-10- OH-AT ratio",
  "PK:amitriptyline/nortriptyline ratio corrected for dose and weight",
  "PK:an influence on plasma levels of lopinavir and efavirenz",
  "PK:antidepressant response",
  "PK:antidepressant serum levels",
  "PK:any pharmacokinetic parameters measured in the study",
  "PK:apparent terminal elimination half-life",
  "PK:area under curve (AUC) of omeprazole racemate",
  "PK:area under plasma concentration of propranolol",
  "PK:area under the curve",
  "PK:area under the curve from baseline to the last measured concentration",
  "PK:area under the plasma concentration-time curve",
  "PK:area under the plasma concentration-time curve values",
  "PK:area under the time-plasma concentration curve (AUC(0-24))",
  "PK:area under the visual analog scale-time curve during the induced state",
  "PK:areas under the serum concentration-time curve",
  "PK:atorvastatin lactonization",
  "PK:baseline LDL cholesterol",
  "PK:baseline cortisol levels",
  "PK:baseline plasma levels of VEGF-A",
  "PK:being a predictor of mitotane plasma concentrations of at least 14 \u00b5g/ml after 3 months of treatment",
  "PK:bioavailability",
  "PK:bioavailability (AUC",
  "PK:bioavailabilty",
  "PK:blood concentration",
  "PK:blood concentration/dosage ratio",
  "PK:blood concentrations",
  "PK:blood pressure",
  "PK:bosentan exposure",
  "PK:cerivastatin intrinsic clearance",
  "PK:changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 1g per day)",
  "PK:changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day)",
  "PK:citalopram AUC and terminal elimination half-life",
  "PK:citalopram oral clearances of citalopram",
  "PK:clearance",
  "PK:clearance of S(+) mirtazapine",
  "PK:clearance of dicloxacillin",
  "PK:clearance of unbound cisplatin",
  "PK:clerance of paclitaxel",
  "PK:clomipramine and desmethyl clomipramine plasma concentration",
  "PK:clopidogrel active metabolite level",
  "PK:codeine metabolism and morphine and glucuronides formation",
  "PK:concentration",
  "PK:concentration-to-adjusted dose ratio",
  "PK:concentration-to-dose ratios",
  "PK:concentration/dose ratio",
  "PK:concentrations of 10-OH-nortriptyline and higher nortriptyline/10-OH-nortriptyline ratio",
  "PK:converting into poor metabolizer after 14 days paroxetine treatments",
  "PK:cotinine levels",
  "PK:creatinine clearance",
  "PK:delayed cortisol response to stress",
  "PK:demethylation clearance of desmethylcitalopram",
  "PK:desipramine elimination half-life and total exposure",
  "PK:desipramine to hydroxy-desipramine ratio",
  "PK:desipramine/2-hydroxy-desipramine ratio",
  "PK:detectable serum drug concentrations or side effects in an infant exposed to paroxetine through mother (*4/*4)",
  "PK:diclofenac/5-hydroxydiclofenac urinary concentration ratio",
  "PK:difference in the dose-normalized steady-state plasma concentration of olanzapine",
  "PK:difference in the metabolic ratio of desmethyl clomipramine (DC)/hydroxy desmethyl clomipramine (HDC)",
  "PK:differences in 5-HMT formation (active metabolite)",
  "PK:differences in AUC of desmethylmirtazapine",
  "PK:differences in C/D plasma concentrations of norfluoxetine or active moiety",
  "PK:differences in Dose-normalized plasma levels of individual enantiomers and of the active moiety",
  "PK:differences in S-CIT treatment dose and serum concentrations of S-CIT",
  "PK:differences in clozapine and N-desmethylclozapine C/D ratios",
  "PK:differences in desmethyl-mirtazapine parameters",
  "PK:differences in digoxin absorption after single oral dose of 1 mg digoxin",
  "PK:differences in dose-adjusted trough serum olanzapine concentrations",
  "PK:differences in dose-normalized plasma levels of individual enantiomers and of the active moiety",
  "PK:differences in drug levels",
  "PK:differences in duloxetine pharmacokinetics parameters",
  "PK:differences in exposure to the active metabolite of prasugrel",
  "PK:differences in fluvoxamine pharmacokinetic parameters (AUC",
  "PK:differences in for sertraline and desmethylsertraline pharmacokinetics",
  "PK:differences in in the fluvoxamine plasma level at 100",
  "PK:differences in mean serum concentrations of sertraline and N-desmethyl sertraline",
  "PK:differences in nortriptyline concentrations",
  "PK:differences in paroxetine daily dose and plasma concentrations",
  "PK:differences in paroxetine plasma concentration",
  "PK:differences in plasma OLZ and metabolite concentrations and on their respective ratios",
  "PK:differences in plasma fluvoxamine concentration",
  "PK:differences in plasma paroxetine concentrations at administered dose above 10mg/day",
  "PK:differences in steady-state plasma concentrations of fluvoxamine and its demethylated metabolite fluvoxamino acid",
  "PK:differences in the areas under the serum concentration-time curve",
  "PK:differences in the fluvoxamine plasma level at 50 mg/day",
  "PK:differences in the plasma metformin concentration versus time curve or the maximum metformin concentration",
  "PK:differences in the ratio of nortriptyline and its metabolite",
  "PK:differences pharmacokinetic parameters",
  "PK:distribution volume",
  "PK:dose",
  "PK:dose of tacrolimus",
  "PK:dose-adjusted AUC24",
  "PK:dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid",
  "PK:dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid-7-O-glucuronide",
  "PK:dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA)",
  "PK:dose-adjusted blood levels",
  "PK:dose-adjusted concentration",
  "PK:dose-adjusted plasma levels",
  "PK:dose-adjusted serum olanzapine N-oxide concentrations",
  "PK:dose-adjusted serum olanzapine concentrations",
  "PK:dose-adjusted tacrolimus blood concentrations",
  "PK:dose-adjusted trough concentration",
  "PK:dose-adjusted trough concentrations",
  "PK:dose-adjusted trough levels",
  "PK:dose-corrected plasma concentrations",
  "PK:dose-corrected plasma concentrations of fluoxetine",
  "PK:dose-corrected plasma concentrations of fluoxetine and the active moiety in patients with two functional CYP2D6 alleles",
  "PK:dose-normalized  Cmax and dose-normalized  AUC0to12 h",
  "PK:dose-normalized R-fluoxetine concentrations and and the active moiety in CYP2D6*1/*1 patients",
  "PK:dose/weight adjusted AUC for mirtazapine",
  "PK:doxorubicin AUC",
  "PK:doxorubicinol AUC",
  "PK:dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide",
  "PK:drug metabolism",
  "PK:duodenal absorption of digoxin after direct delivery to the surface of the duodenum by endoscope",
  "PK:efflux of rhodamine from CD56+ natural killer cells",
  "PK:elevated plasma concentrations",
  "PK:elimination clearance of dFdU",
  "PK:elimination clearance of dFdU and formation clearance of dFdCTP",
  "PK:elimination half-life and drug exposure",
  "PK:elimination rate",
  "PK:enzyme activity and decreased paclitaxel 6 a -hydroxylase activity in vitro",
  "PK:erythromycin breath test",
  "PK:erythromycin metabolism",
  "PK:etravirine clearance",
  "PK:exposure",
  "PK:exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance",
  "PK:exposure to clopidogrel active metabolite",
  "PK:exposure to drug",
  "PK:exposure to timolol (higher area-under-curve",
  "PK:fluoxetine plasma concentration",
  "PK:fluoxetine/(S)-norfluoxetine ratio",
  "PK:fluvoxamine plasma concentrations",
  "PK:formation clearance of dFdCTP",
  "PK:formation of metabolites",
  "PK:glucuronidated metabolites of olanzapine",
  "PK:glucuronidation",
  "PK:glucuronidation metabolic ratios",
  "PK:glucuronidation of nicotine",
  "PK:higher plasma concentrations of O-desmethyltramadol",
  "PK:higher plasma concentrations of celecoxib",
  "PK:hydroxybupropion concentrations",
  "PK:hydroxybupropion concentrations and hydroxybupropion/bupropion ratio",
  "PK:imatinib clearance",
  "PK:imipramine and desipramine plasma concentrations",
  "PK:impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel",
  "PK:impaired metabolic activity",
  "PK:in vitro intrinsic clearance of S-warfarin with the cDNA-expressed R150H protein",
  "PK:in vivo metabolism of (S)-warfarin but not (R)-warfarin",
  "PK:increased half-life at overdose",
  "PK:inhibition of metabolism",
  "PK:inhibition of sertraline N-demethylation by anti-CYP2C8/9/19",
  "PK:insulin secretion at baseline",
  "PK:intracellular PBMC exposure",
  "PK:intracellular and blood concentration",
  "PK:intracellular tenofovir diphosphate (TFV-DP) concentrations",
  "PK:intraindividual variability",
  "PK:intrapatient variability",
  "PK:lack of increase in metformin concentrations",
  "PK:levels of 6-thioguanine nucleotides",
  "PK:levels of clopidogrel active metabolite",
  "PK:levels of erythrocyte 6-thioguanine nucleotide metabolites",
  "PK:liver injury",
  "PK:log metabolic ratio of amitriptyline/nortriptyline",
  "PK:low or undetectable paroxetine plasma concentration",
  "PK:lower nevirapine plasma concentrations",
  "PK:lower relative dose-adjusted serum concentrations of escitalopram and higher relative dose-adjusted serum concentrations of N-desmethyl S-citalopram and propionic acid metabolite",
  "PK:maximum plasma concentration of 10-hydroxy nortriptyline",
  "PK:mean AUC",
  "PK:mean amitriptyline concentrations corrected for dose and weight",
  "PK:mean area under the plasma concentration-time curve (AUC) of desipramine",
  "PK:mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine",
  "PK:mean escitalopram concentration",
  "PK:mean logarithm escitalopram concentration",
  "PK:mean logarithm escitalopram concentration and higher mean metabolic ratio",
  "PK:mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication",
  "PK:mean peak concentration in plasma and area under the plasma concentration",
  "PK:mean peak plasma concentration of H4",
  "PK:mean plasma AUC",
  "PK:mean plasma concentration of oxymorphone and lower mean oxymorphone/oxycodone ratio",
  "PK:mean plasma drug concentrations",
  "PK:mean serum concentrations of sertraline and N-desmethyl sertraline",
  "PK:median AUC",
  "PK:median concentration/dose ratio and median parent drug/metabolite ratio",
  "PK:median oral clearance of doxepin",
  "PK:median paroxetine steady-state plasma concentration",
  "PK:median plasma lopinavir Cmin and C2-6",
  "PK:median zidovudine-triphosphate concentration at a marginally significance after gender adjustment",
  "PK:metabolic ratio",
  "PK:metabolic ratio (defined as ratio of omeprazole to its metabolites) of 5-hydroxyomeprazole",
  "PK:metabolic ratio (defined as ratio of omeprazole to its metabolites) of 5-hydroxyomeprazole and R-5-hydroxyomeprazole",
  "PK:metabolic ratio CIT/DCIT values",
  "PK:metabolic ratio CIT/DCIT values and mean citalopram dose",
  "PK:metabolic ratio of midazolam",
  "PK:metabolic ratios of desipamine",
  "PK:metabolism",
  "PK:metabolism of S-mephenytoin and tolbutamide",
  "PK:metabolism of amodiaquine in vitro",
  "PK:metabolism of amodiaquine in vitro (three fold higher Km and six fold lower intrinsic clearance)",
  "PK:metabolism/clearance of paclitaxel (reduced paclitaxel 6a-hydroxylase activities) in vitro",
  "PK:metformin secretory clearance",
  "PK:metformin uptake in HEK-293 cells and reduction in protein expression levels",
  "PK:methadone plasma levels",
  "PK:methotrexate polyglutamate (MTXPG3-5) levels",
  "PK:methotrexate polyglutamate accumulation",
  "PK:mid-dose plasma concentrations",
  "PK:midazolam metabolic ratios by 45%",
  "PK:minimum plasma concentrations",
  "PK:minimum plasma or PBMC concentrations",
  "PK:mitotane plasma concentrations",
  "PK:nicotine glucuronidation",
  "PK:no catalytic activity",
  "PK:non-inducible thiotepa clearance and decreased tepa clearance",
  "PK:nonsignificantly higher paroxetine concentration",
  "PK:nortriptyline concentrations corrected for dose and weight",
  "PK:nortriptyline/(E)-10-OH-NT ratio",
  "PK:olanzapine exposure",
  "PK:oral clearance (CL) of atazanavir",
  "PK:oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia",
  "PK:oral clearance (CL/F) of omeprazole racemate",
  "PK:oral clearance of A77 1726 a metabolite",
  "PK:oral clearance of atorvastatin",
  "PK:oral clearance of citalopram",
  "PK:oral clearance or elimination half-life of propranolol",
  "PK:oxazepam oral clearance",
  "PK:paroxetine Vm (maximal rate)",
  "PK:paroxetine levels",
  "PK:paroxetine plasma concentration",
  "PK:paroxetine plasma concentration at an administered dose of 30mg/day",
  "PK:paroxetine plasma concentrations increased during the course of pregnancy",
  "PK:paroxetine serum concentration",
  "PK:paroxetine serum concentrations (Cmin)",
  "PK:peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) of clopidogrel and its active metabolite after a single oral loading dose of 300 or 600 mg",
  "PK:percentage change in LDL-cholesterol levels",
  "PK:pharmacokinetics",
  "PK:pharmacokinetics of flecainide in healthy Chinese subjects",
  "PK:phenytoin metabolic clearance (PMC) and phenytoin metabolic ratio (PMR)",
  "PK:pitavastatin plasma concentrations (AUC) and Cmax",
  "PK:plamsa exposure",
  "PK:plasma 4beta-OHC/Chol ratio",
  "PK:plasma AUC",
  "PK:plasma Cmin values",
  "PK:plasma MK-4 concentration",
  "PK:plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT)",
  "PK:plasma concentration",
  "PK:plasma concentration (p<0.001)",
  "PK:plasma concentration (p=0.028)",
  "PK:plasma concentration (p=0.509)",
  "PK:plasma concentration of efavirenz",
  "PK:plasma concentration of imipramine and desipramine",
  "PK:plasma concentration of the 4-ene-VPA metabolite",
  "PK:plasma concentrations",
  "PK:plasma concentrations of O-desmethyltramadol",
  "PK:plasma concentrations of clomipramine and desmethylclomipramine",
  "PK:plasma concentrations of diflomotecan",
  "PK:plasma concentrations of fluoxetine and decreased nor-fluoxetine concentrations",
  "PK:plasma concentrations of metoprolol",
  "PK:plasma concentrations of metoprolol and greater reductions in heart rate",
  "PK:plasma concentrations of rosuvastatin",
  "PK:plasma drug concentration",
  "PK:plasma drug levels",
  "PK:plasma efavirenz exposure",
  "PK:plasma efavirenz exposure (AUC) during the first 24 weeks of antiretroviral therapy",
  "PK:plasma efavirenz levels",
  "PK:plasma endoxifen level",
  "PK:plasma exposure",
  "PK:plasma exposure to the active metabolite of clopidogrel",
  "PK:plasma fluorouracil",
  "PK:plasma free phenytoin concentration",
  "PK:plasma level",
  "PK:plasma level of morphine",
  "PK:plasma levels",
  "PK:plasma levels of morphine",
  "PK:plasma methylmercaptopurine nucleotides levels",
  "PK:plasma metoprolol concentrations",
  "PK:plasma nortriptyline",
  "PK:plasma or PBMC concentrations",
  "PK:plasma oxymorphone/oxycodone ratio",
  "PK:plasma predose concentration (Ctrough)",
  "PK:plasma ratio citalopram (CIT)/N-desmethylCIT (DCIT)",
  "PK:plasma thioguanine nucleotides metabolites",
  "PK:plasma timolol concentration and excerice heart rate reduction",
  "PK:poor metabolizer phenotype",
  "PK:pravastatin plasma concentrations (AUC)",
  "PK:pravastatin plasma concentrations (AUC) and Cmax",
  "PK:prolonged high concentrations",
  "PK:racemic",
  "PK:ratio of 1",
  "PK:ratio of desmethylCIT/N-didesmethylCIT plasma",
  "PK:ratio of nortriptyline and its metabolite (NT/EHNT)",
  "PK:red blood cell folate",
  "PK:relative bioavailability of pravastatin",
  "PK:relative dose-adjusted serum concentrations of escitalopram and lower relative dose-adjusted serum concentrations of N-desmethyl S-citalopram and propionic acid metabolite",
  "PK:renal and secretory clearance of metformin",
  "PK:renal clearance and secretion clearance of metformin",
  "PK:repaglinide AUC",
  "PK:repaglinide exposure (decreased AUC and increased clearance)",
  "PK:repaglinide plasma concentration (AUC) and Cmax",
  "PK:residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol",
  "PK:resistance",
  "PK:rifampicin exposure",
  "PK:risk of being underdosed",
  "PK:serum concentration",
  "PK:serum concentration of 9-hydroxyrisperidone or sum of risperidone and 9-hydroxyrisperidone",
  "PK:serum concentration of dehydroaripiprazole",
  "PK:serum concentrations",
  "PK:serum concentrations of S(+)-mirtazapine",
  "PK:serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios",
  "PK:serum concentrations of the parent drug olanzapine",
  "PK:serum hydrazine concentrations",
  "PK:serum uric acid",
  "PK:shorter continin half-life",
  "PK:significant differences in any of the olanzapine pharmacokinetic parameters",
  "PK:significantly higher (S)-fluoxetine and lower and (S)-norfluoxetine concentrations",
  "PK:significantly larger mean AUC of oseltamivir",
  "PK:significantly lower transport efficiency (Vmax/Km) and clearance (Clin )",
  "PK:stable dose",
  "PK:steady state concentration per dosage",
  "PK:steady-state plasma concentrations of desipramine/daily dose of desipramine/body weight",
  "PK:sterol/bile acid metabolites",
  "PK:systemic exposure (AUC) and lower oral clearance of flecainide",
  "PK:tacrolimus concentration to dose ratio (C/D ratio)",
  "PK:tacrolimus dose-adjusted blood concentration",
  "PK:tacrolimus plasma trough levels and severely diminished tacrolimus clearance",
  "PK:tenofovir renal clearance",
  "PK:the K(m) for the nucleoside phosphonate analogs",
  "PK:the intrinsic metabolic activity (V(max)/K(m))",
  "PK:the maximal elimination rate (Vmax)",
  "PK:the mean maximal elimination rate (Vmax)",
  "PK:the mean maximal elimination rates (V(max))",
  "PK:time to achieve therapeutic window",
  "PK:time to reach stable dose",
  "PK:time to reach stable dose of tacrolimus",
  "PK:time to stable dose",
  "PK:tolterodine exposure and increased active metabolite (5-HM) concentrations",
  "PK:tolterodine exposure and unquantifiable active metabolite (5-HM) concentrations",
  "PK:total clearance of racemic mirtazapine",
  "PK:tramadol clearance in Chinese volunteers",
  "PK:tramadol metabolism",
  "PK:transport",
  "PK:trough ( R",
  "PK:trough blood concentration",
  "PK:trough blood concentration normalized for the daily dose (C) per kilogram body weight (D) (C/D",
  "PK:trough concentration",
  "PK:trough concentrations",
  "PK:trough levels",
  "PK:trough plasma levels",
  "PK:trough rosiglitazone steady-state concentration",
  "PK:unbound oral clearance for S-warfarin",
  "PK:unbound oral clearance of S-warfarin and lower R- to S-warfarin plasma concentration ratio",
  "PK:undetectable or low paroxetine serum concentrations",
  "PK:undetectable paroxetine plasma concentration",
  "PK:undetectable paroxetine serum concentration",
  "PK:variation in mycophenolic acid pharmacokinetic parameters",
  "PK:venlafaxine concentration per unit dose",
  "PK:venlafaxine levels",
  "PK:very low nortriptyline after 7 days of treatment",
  "PK:volume of distribution",
  "Portal",
  "Postoperative",
  "R-5-hydroxyomeprazole and S-5-hydroxyomeprazole",
  "R-omeprazole and S-omeprazole",
  "S )-methadone plasma concentrations",
  "S-ibuprofen and R-ibuprofen metabolism",
  "Second Primary",
  "Sensorineural",
  "Side Effect: cardiovascular events",
  "Side Effect: side effects",
  "Side Effect:ACEI-related cough",
  "Side Effect:ADR",
  "Side Effect:ALT activity",
  "Side Effect:Abdominal Pain",
  "Side Effect:Abnormalities",
  "Side Effect:Abortion",
  "Side Effect:Acquired Long QT Syndrome (aLQTS)",
  "Side Effect:Acute cellular rejection",
  "Side Effect:Acute coronary syndrome",
  "Side Effect:Aggression",
  "Side Effect:Agitation",
  "Side Effect:Agranulocytosis",
  "Side Effect:Albuminuria",
  "Side Effect:Alcohol abuse",
  "Side Effect:Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors",
  "Side Effect:Alopecia",
  "Side Effect:Amenorrhea",
  "Side Effect:Anaphylaxis",
  "Side Effect:Anemia",
  "Side Effect:Angina Pectoris",
  "Side Effect:Angioedema",
  "Side Effect:Anorexia",
  "Side Effect:Anxiety Disorders",
  "Side Effect:Apnea",
  "Side Effect:Arthralgia",
  "Side Effect:Arthritis",
  "Side Effect:Aspirin-Exacerbated Respiratory Disease",
  "Side Effect:Aspirin-induced asthma",
  "Side Effect:Asthenia",
  "Side Effect:Asthma",
  "Side Effect:Asthma-related ER visit or hospitalization",
  "Side Effect:Ataxia",
  "Side Effect:Atrial Fibrillation",
  "Side Effect:Autonomic Nervous System Disorder",
  "Side Effect:Binge eating disorder",
  "Side Effect:Blood Coagulation Disorders",
  "Side Effect:Bone Marrow Disorder",
  "Side Effect:Bone Marrow toxicity",
  "Side Effect:Bradycardia",
  "Side Effect:Brain Edema",
  "Side Effect:Brain Ischemia",
  "Side Effect:Brugada syndrome",
  "Side Effect:Bullous Pemphigoid",
  "Side Effect:Butyrylcholinesterase deficiency",
  "Side Effect:CNS adverse events",
  "Side Effect:CNS depression",
  "Side Effect:CNS depression and/or death of breastfeeding neonate",
  "Side Effect:CNS depression in breast-feeding infants",
  "Side Effect:COMT inhibitor-induced toxicity",
  "Side Effect:Carbamazepine-induced hypersensitivity syndrome",
  "Side Effect:Carbamazepine-induced hypersensitivity syndrome (HSS)",
  "Side Effect:Carcinoma",
  "Side Effect:Cardiac rhythm disease",
  "Side Effect:Cardiomyopathies",
  "Side Effect:Cardiomyopathy",
  "Side Effect:Cardiotoxicity",
  "Side Effect:Cardiovascular Disease",
  "Side Effect:Cataract",
  "Side Effect:Central Nervous System Disorder",
  "Side Effect:Cerebral Palsy",
  "Side Effect:Chest Pain",
  "Side Effect:Cholelithiasis",
  "Side Effect:Cocaine dependence",
  "Side Effect:Cognitive disorder",
  "Side Effect:Colitis",
  "Side Effect:Confusion",
  "Side Effect:Constipation",
  "Side Effect:Coronary Artery Disease",
  "Side Effect:Coronary Disease",
  "Side Effect:Cough",
  "Side Effect:Craving",
  "Side Effect:Cryoglobulinemia",
  "Side Effect:Cushing Syndrome",
  "Side Effect:Cystic fibrosis pulmonary exacerbation",
  "Side Effect:Cystitis",
  "Side Effect:Death",
  "Side Effect:Death or Severe Respiratory Depression",
  "Side Effect:Decreased glomerular filtration rate",
  "Side Effect:Delirium",
  "Side Effect:Dependence",
  "Side Effect:Depression",
  "Side Effect:Dermatitis",
  "Side Effect:Diabetes Mellitus",
  "Side Effect:Diarrhea",
  "Side Effect:Diminished ability to concentrate",
  "Side Effect:Diplopia",
  "Side Effect:Discontinuation",
  "Side Effect:Dizziness",
  "Side Effect:Dose reduction",
  "Side Effect:Drug Hypersensitivity",
  "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
  "Side Effect:Drug Toxicity",
  "Side Effect:Drug interaction with drug",
  "Side Effect:Drug psychosis",
  "Side Effect:Drug-induced liver injury",
  "Side Effect:Dry mouth",
  "Side Effect:Dysarthria",
  "Side Effect:Dyskinesia",
  "Side Effect:Dyskinesias",
  "Side Effect:Dyslipidaemia",
  "Side Effect:Dyspepsia",
  "Side Effect:Dyspnea",
  "Side Effect:Dystonia",
  "Side Effect:Ectropion",
  "Side Effect:Edema",
  "Side Effect:Elevated circulating creatine kinase concentration",
  "Side Effect:Elevated diastolic blood pressure",
  "Side Effect:Elevated liver enzymes",
  "Side Effect:Elevated systolic blood pressure",
  "Side Effect:Encephalopathy",
  "Side Effect:Endometrial Hyperplasia",
  "Side Effect:Enterocolitis",
  "Side Effect:Epidermal Necrolysis",
  "Side Effect:Epilepsy",
  "Side Effect:Epistaxis",
  "Side Effect:Erectile Dysfunction",
  "Side Effect:Erythema",
  "Side Effect:Erythema multiforme",
  "Side Effect:Esophagitis",
  "Side Effect:Exanthema",
  "Side Effect:Eye Diseases",
  "Side Effect:FEV1 decrease after aspirin challenge",
  "Side Effect:Fanconi renotubular syndrome",
  "Side Effect:Fatigue",
  "Side Effect:Febrile neutropenia",
  "Side Effect:Fever",
  "Side Effect:Flushing",
  "Side Effect:Folic Acid Deficiency Anemia",
  "Side Effect:Fractures",
  "Side Effect:GI intolerance",
  "Side Effect:GI toxicity",
  "Side Effect:Galactorrhea",
  "Side Effect:Gastritis",
  "Side Effect:Gastrointestinal Hemorrhage",
  "Side Effect:Gastrointestinal side effects",
  "Side Effect:Gastrointestinal toxicity",
  "Side Effect:Gingival Overgrowth",
  "Side Effect:Graft vs Host Disease",
  "Side Effect:Hallucinations",
  "Side Effect:Hand-foot syndrome",
  "Side Effect:Headache",
  "Side Effect:Hearing Disorders",
  "Side Effect:Hearing Loss",
  "Side Effect:Hematologic Disorder",
  "Side Effect:Hematoma",
  "Side Effect:Hematuria",
  "Side Effect:Hemolysis",
  "Side Effect:Hemolysis and subsequent death",
  "Side Effect:Hemolytic Anemia",
  "Side Effect:Hemorrhage",
  "Side Effect:Heparin-induced thrombocytopenia",
  "Side Effect:Hepatic Veno-Occlusive Disease",
  "Side Effect:Hepatitis",
  "Side Effect:Hepatocellular Carcinoma",
  "Side Effect:Heroin Dependence",
  "Side Effect:Hot Flashes",
  "Side Effect:Hyperalgesia",
  "Side Effect:Hyperammonemia",
  "Side Effect:Hyperbilirubinemia",
  "Side Effect:Hypercholesterolemia",
  "Side Effect:Hyperglycemia",
  "Side Effect:Hyperhidrosis",
  "Side Effect:Hyperkinesis",
  "Side Effect:Hyperlipidemias",
  "Side Effect:Hyperprolactinemia",
  "Side Effect:Hypersensitivity",
  "Side Effect:Hypersensitivity Syndrome",
  "Side Effect:Hypertension",
  "Side Effect:Hypertriglyceridemia",
  "Side Effect:Hyperuricemia",
  "Side Effect:Hypoglycemia",
  "Side Effect:Hyponatremia",
  "Side Effect:Hypotensive disorder",
  "Side Effect:Hypothyroidism",
  "Side Effect:Hypoventilation",
  "Side Effect:IQ",
  "Side Effect:Illusions",
  "Side Effect:Impulse control disorder",
  "Side Effect:Inappropriate ADH Syndrome",
  "Side Effect:Infectious disease",
  "Side Effect:Inflammation",
  "Side Effect:Insomnia",
  "Side Effect:Insulin Resistance",
  "Side Effect:Interstitial Lung Diseases",
  "Side Effect:Intracranial Hemorrhages",
  "Side Effect:Jaundice",
  "Side Effect:Kidney Disorder",
  "Side Effect:Left Ventricular Dysfunction",
  "Side Effect:Leiomyoma",
  "Side Effect:Leukopenia",
  "Side Effect:Life-threatening opioid intoxication",
  "Side Effect:Lipodystrophy",
  "Side Effect:Liver Disorder",
  "Side Effect:Liver Failure",
  "Side Effect:Long QT Syndrome",
  "Side Effect:Lupus erythematosus",
  "Side Effect:Lymphopenia",
  "Side Effect:Maculopapular Exanthema",
  "Side Effect:Major Adverse Cardiac Events (MACE)",
  "Side Effect:Malignant Hyperthermia",
  "Side Effect:Memory impairment",
  "Side Effect:Metabolic Syndrome",
  "Side Effect:Methamphetamine dependence",
  "Side Effect:Methemoglobinemia",
  "Side Effect:Mortality",
  "Side Effect:Mucositis",
  "Side Effect:Muscle Rigidity",
  "Side Effect:Muscle spasm",
  "Side Effect:Muscular Diseases",
  "Side Effect:Musculoskeletal pain",
  "Side Effect:Myalgia",
  "Side Effect:Myelosuppression",
  "Side Effect:Myocardial Infarction",
  "Side Effect:Myoclonus",
  "Side Effect:Nail disorder",
  "Side Effect:Narcolepsy",
  "Side Effect:Nausea",
  "Side Effect:Nephrolithiasis",
  "Side Effect:Nephrotoxicity",
  "Side Effect:Neuropathic pain",
  "Side Effect:Neurotoxicity",
  "Side Effect:Neurotoxicity Syndromes",
  "Side Effect:Neutropenia",
  "Side Effect:Neutropenia in HCV-HIV coinfected patients",
  "Side Effect:Nevirapine-induced rash",
  "Side Effect:Obesity",
  "Side Effect:Ocular Hypertension",
  "Side Effect:Oliguria",
  "Side Effect:Opioid-Related Disorders",
  "Side Effect:Oral Ulcer",
  "Side Effect:Orthostatic Hypotension",
  "Side Effect:Osteonecrosis",
  "Side Effect:Osteonecrosis of the jaw",
  "Side Effect:Ototoxicity",
  "Side Effect:Ovarian Cysts",
  "Side Effect:Overall survival",
  "Side Effect:Overdose",
  "Side Effect:PFA-closure time",
  "Side Effect:Pain",
  "Side Effect:Pancreatitis",
  "Side Effect:Pancytopenia",
  "Side Effect:Paresthesia",
  "Side Effect:Parkinsonian Disorder",
  "Side Effect:Pathologic nystagmus",
  "Side Effect:Peptic Ulcer Disease",
  "Side Effect:Peripheral Nervous System Diseases",
  "Side Effect:Photophobia",
  "Side Effect:Physiological sexual disorder",
  "Side Effect:Pneumonia",
  "Side Effect:Pneumonitis",
  "Side Effect:Polyps",
  "Side Effect:Postoperative Complications",
  "Side Effect:Postoperative Nausea and Vomiting",
  "Side Effect:Primary ovarian failure",
  "Side Effect:Progression-free survival",
  "Side Effect:Prolonged QTc interval",
  "Side Effect:Proteinuria",
  "Side Effect:Pruritus",
  "Side Effect:Psoriasis",
  "Side Effect:Psychomotor Agitation",
  "Side Effect:Psychotic Disorder",
  "Side Effect:QT interval",
  "Side Effect:QTc interval",
  "Side Effect:QTc prolongation",
  "Side Effect:Recurrence",
  "Side Effect:Renal interstitial fibrosis",
  "Side Effect:Respiratory Insufficiency",
  "Side Effect:Rhabdomyolysis",
  "Side Effect:Rheumatoid Nodule",
  "Side Effect:Seizures",
  "Side Effect:Sepsis",
  "Side Effect:Serotonin Syndrome",
  "Side Effect:Severe Cutaneous Adverse Reactions",
  "Side Effect:Sexual adverse events",
  "Side Effect:Shortened QT interval",
  "Side Effect:Sialoadenitis",
  "Side Effect:Sialorrhea",
  "Side Effect:Side Effects",
  "Side Effect:Side Effects Scale scores",
  "Side Effect:Skin Disorder",
  "Side Effect:Skin Neoplasms",
  "Side Effect:Sleep Apnea Syndromes",
  "Side Effect:Sleep Disorders",
  "Side Effect:Sleep Initiation and Maintenance Disorders",
  "Side Effect:Somnolence",
  "Side Effect:Status Epilepticus",
  "Side Effect:Stevens-Johnson Syndrome",
  "Side Effect:Stevens-Johnson Syndrome/Epidermal Necrolysis",
  "Side Effect:Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions",
  "Side Effect:Stomatitis",
  "Side Effect:Stroke",
  "Side Effect:Sudden cardiac death",
  "Side Effect:Suicide",
  "Side Effect:Syncope",
  "Side Effect:Systemic lupus erythematosus",
  "Side Effect:Tachycardia",
  "Side Effect:Tardive Dyskinesia",
  "Side Effect:Thrombocytopenia",
  "Side Effect:Thromboembolism",
  "Side Effect:Thrombotic disease",
  "Side Effect:Thyrotoxicosis",
  "Side Effect:Tinnitus",
  "Side Effect:Tobacco Use Disorder",
  "Side Effect:Torsades de Pointes",
  "Side Effect:Torticollis",
  "Side Effect:Toxic Epidermal Necrolysis",
  "Side Effect:Toxic liver disease",
  "Side Effect:Transient Ischemic Attack",
  "Side Effect:Transplant rejection",
  "Side Effect:Treatment failure",
  "Side Effect:Treatment interruption",
  "Side Effect:Treatment modification",
  "Side Effect:Tremor",
  "Side Effect:Trismus",
  "Side Effect:Unconsciousness",
  "Side Effect:Unspecified conjunctivitis",
  "Side Effect:Unstable Angina",
  "Side Effect:Urinary Retention",
  "Side Effect:Urinary Tract Infections",
  "Side Effect:Urticaria",
  "Side Effect:Uterine disorder",
  "Side Effect:Venous Thrombosis",
  "Side Effect:Venous thromboembolism",
  "Side Effect:Ventricular Fibrillation",
  "Side Effect:Vertigo",
  "Side Effect:Virus Diseases",
  "Side Effect:Vision Disorder",
  "Side Effect:Vomiting",
  "Side Effect:Weight gain",
  "Side Effect:Wheezing",
  "Side Effect:a drop in hemoglobin levels of 20g/L or more",
  "Side Effect:a mild increase of liver enzymes",
  "Side Effect:a reduction in hemoglobin value",
  "Side Effect:a significantly higher odds of Musculoskeletal adverse events (MSAEs) in postmenopausal hormone receptor (HR)-positive breast cancer patients",
  "Side Effect:a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients",
  "Side Effect:abdominal pain",
  "Side Effect:abnormal dreams",
  "Side Effect:acetylsalicylic acid-intolerant chronic urticaria",
  "Side Effect:acute gastrointestinal bleeding",
  "Side Effect:acute lung injury",
  "Side Effect:adverse cardiovascular events",
  "Side Effect:adverse cardiovascular outcomes",
  "Side Effect:adverse clinical events",
  "Side Effect:adverse cognitive effects",
  "Side Effect:adverse drug event",
  "Side Effect:adverse drug events",
  "Side Effect:adverse drug reaction",
  "Side Effect:adverse drug reaction after the second switch in treatment",
  "Side Effect:adverse drug reactions",
  "Side Effect:adverse effect burden",
  "Side Effect:adverse effects",
  "Side Effect:adverse events",
  "Side Effect:adverse outcome",
  "Side Effect:adverse reaction",
  "Side Effect:adverse reactions",
  "Side Effect:adverse side effects",
  "Side Effect:agitation and dysphoria",
  "Side Effect:akathisia",
  "Side Effect:all",
  "Side Effect:all and minor hemorrhage",
  "Side Effect:all statin-induced myopathy and severe myopathy",
  "Side Effect:all-cause mortality",
  "Side Effect:aminotransferase activity",
  "Side Effect:amiodarone-induced ventricular arrhythmia and QT prolongation",
  "Side Effect:anemia",
  "Side Effect:anxiety",
  "Side Effect:any adverse drug event",
  "Side Effect:any grade 3 adverse event",
  "Side Effect:appetite suppression",
  "Side Effect:arousal dysfunction",
  "Side Effect:aspirin hypersensitivity",
  "Side Effect:aspirin intolerance",
  "Side Effect:aspirin resistance",
  "Side Effect:aspirin-intolerant asthma",
  "Side Effect:aspirin-intolerant chronic urticaria",
  "Side Effect:asthma",
  "Side Effect:atherothrombotic events during the 6-year follow up in patients with mechanical heart valve replacement",
  "Side Effect:average cumulative neurotoxicity grade",
  "Side Effect:baseline adiponectin and with greater adiponectin decline",
  "Side Effect:behavioral disinhibition",
  "Side Effect:being overanticoagulated",
  "Side Effect:biopsy-proven acute rejection",
  "Side Effect:bleeding",
  "Side Effect:bleeding complications",
  "Side Effect:bleeding events",
  "Side Effect:bleeding events during the 6-year follow up in patients with mechanical heart valve replacement",
  "Side Effect:bleeding time",
  "Side Effect:bleedings events",
  "Side Effect:blood loss",
  "Side Effect:blood pressure",
  "Side Effect:body weight gain",
  "Side Effect:bone density",
  "Side Effect:bone marrow suppression",
  "Side Effect:bone marrow toxicity",
  "Side Effect:carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)",
  "Side Effect:carbamazepine-induced hypersensitivity",
  "Side Effect:cardiac damage",
  "Side Effect:cardiotoxicity",
  "Side Effect:cardiovascular adverse reactions",
  "Side Effect:cardiovascular effects",
  "Side Effect:cardiovascular event",
  "Side Effect:cardiovascular events",
  "Side Effect:cardiovascular events (composite of cardiac death",
  "Side Effect:cardiovascular events in patients undergoing PCI",
  "Side Effect:cardiovascular toxicity and symptoms",
  "Side Effect:central nervous system adverse side effects",
  "Side Effect:change in Hip Bone Mineral Density",
  "Side Effect:change in Lumbar Bone Mineral Density",
  "Side Effect:changes in lipids",
  "Side Effect:chest pressure",
  "Side Effect:clomipramine-induced prolactin release",
  "Side Effect:clopidogrel resistance",
  "Side Effect:composite ischemic events",
  "Side Effect:composite outcome of non-fatal MI",
  "Side Effect:cutaneous reactions",
  "Side Effect:decline in FEV 1 after aspirin provocation",
  "Side Effect:decline of forced expiratory volume in 1s (FEV(1)) by aspirin provocation",
  "Side Effect:decreased hemocrit levels",
  "Side Effect:delayed graft function",
  "Side Effect:deliberate self-harm",
  "Side Effect:dermatologic toxicity",
  "Side Effect:diabetes",
  "Side Effect:diarrhea within 24 hours and Thrombocytopenia",
  "Side Effect:diminished estimated glomerular filtration rate (eGFR) during the first year after engraftment",
  "Side Effect:diphenylhydantoin-induced skin rash",
  "Side Effect:discontinuation",
  "Side Effect:discontinuation syndrome",
  "Side Effect:discontinuations due to adverse events and greater severity of side effects",
  "Side Effect:dose decrease or switch to another cholesterol-lowering drug",
  "Side Effect:dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg",
  "Side Effect:dose delay",
  "Side Effect:dose reduction",
  "Side Effect:dose reduction to increase tolerability",
  "Side Effect:dose reductions due to toxicity",
  "Side Effect:doxepin intoxication",
  "Side Effect:drug dosage altered",
  "Side Effect:drug induced liver injury",
  "Side Effect:drug-drug pharmacokinetic interaction",
  "Side Effect:drug-induced liver injury",
  "Side Effect:drug-induced lupus erythematosus due to hydralazine",
  "Side Effect:drug-induced ventricular arrhythmia and QT prolongation",
  "Side Effect:dysphoria",
  "Side Effect:earlier onset of bortezomib-induced peripheral neuropathy",
  "Side Effect:early (< 3 months) termination of efavirenz therapy",
  "Side Effect:early major adverse cardiovascular events (MACE)",
  "Side Effect:elective PCI-related peri-procedural myocardial damage",
  "Side Effect:elevated insulin levels",
  "Side Effect:elevated transaminases",
  "Side Effect:end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance",
  "Side Effect:end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance.",
  "Side Effect:extrapyramidal symptoms",
  "Side Effect:extrapyrimidal side effects (EPS)",
  "Side Effect:fasting glucose",
  "Side Effect:flu-like symptoms",
  "Side Effect:frequency of adverse effects",
  "Side Effect:gastrointestinal bleeding",
  "Side Effect:gastrointestinal disturbances in HCV-HIV coinfected patients",
  "Side Effect:gastrointestinal side effects",
  "Side Effect:gastrointestinal toxicities",
  "Side Effect:gastrointestinal toxicity",
  "Side Effect:general adverse reactions",
  "Side Effect:general side-effect burden",
  "Side Effect:general side-effects",
  "Side Effect:glucose elevation",
  "Side Effect:grade 3 hypertension",
  "Side Effect:grade 3 or 4 gastrointestinal toxicity",
  "Side Effect:grade 3 or 4 toxic effects",
  "Side Effect:grade 3-4 nonhematological toxicity",
  "Side Effect:grade 3-4 overall toxicity",
  "Side Effect:grade III hand foot syndrome",
  "Side Effect:grade III/IV liver toxicity",
  "Side Effect:graft vs host disease",
  "Side Effect:haematological toxicity",
  "Side Effect:haematological toxicity or hepatotoxicity",
  "Side Effect:haematopoietic toxicity",
  "Side Effect:hearing and vision-related side-effects",
  "Side Effect:hearing impairment",
  "Side Effect:heart palpitations",
  "Side Effect:heart rate",
  "Side Effect:heaviness in arms",
  "Side Effect:hematologic toxicity",
  "Side Effect:hematological indices",
  "Side Effect:hematological toxicity",
  "Side Effect:hematotoxicity",
  "Side Effect:hematotoxicity or hepatotoxicity",
  "Side Effect:hemoglobin levels",
  "Side Effect:hemolysis",
  "Side Effect:hemorrhage",
  "Side Effect:hemorrhagic cystitis",
  "Side Effect:hemorrhagic transformation",
  "Side Effect:hepatic toxicity",
  "Side Effect:hepatocellular injury",
  "Side Effect:hepatotoxicity",
  "Side Effect:hepatotoxicty",
  "Side Effect:high on-treatment platelet reactivity",
  "Side Effect:higher composite har outcome (cardiac death",
  "Side Effect:higher mean toxicity score",
  "Side Effect:hot flashes",
  "Side Effect:hyper sensitivity to coumarin anticoagulants with multiple bleeding episodes and supra-elevated International Normalized Ratios",
  "Side Effect:hyperhidrosis",
  "Side Effect:hypersensitivity",
  "Side Effect:hypomagnesemia primary",
  "Side Effect:hyponatraemia",
  "Side Effect:iNOS expression and fewer adverse events",
  "Side Effect:impaired motor performance",
  "Side Effect:in total cholesterol in postmenopausal woman and increase in triglycerides and decrease in high density lipoprotein in premenopausal women",
  "Side Effect:increase in uric acid level",
  "Side Effect:increased nicotine toxicity and cardiovascular effects in non-smokers",
  "Side Effect:increased pulse rate",
  "Side Effect:infusion related reaction",
  "Side Effect:insomnia",
  "Side Effect:interval of therapy to leukopenia onset",
  "Side Effect:intolerability",
  "Side Effect:intolerance",
  "Side Effect:ischaemic events",
  "Side Effect:ischaemic stroke",
  "Side Effect:ischemic events",
  "Side Effect:ischemic stroke",
  "Side Effect:kidney tubular dysfunction",
  "Side Effect:leukocytes and neutrophils",
  "Side Effect:leukopenia",
  "Side Effect:liver injury",
  "Side Effect:locomotor activity",
  "Side Effect:low leukocyte counts",
  "Side Effect:low-density lipoprotein cholesterol",
  "Side Effect:lower final daily dose",
  "Side Effect:lumbar bone loss",
  "Side Effect:lung function",
  "Side Effect:maculopapular exanthema",
  "Side Effect:major  but not minor hemorrhage",
  "Side Effect:major adverse cardiac and cerebrovascular events",
  "Side Effect:major adverse cardiovascular events",
  "Side Effect:major adverse cardiovascular events (MACE) (more than one year)",
  "Side Effect:major adverse cardiovascular events (MACE) (more than one year) when receiving a loading dose of 300 mg",
  "Side Effect:major bleeding",
  "Side Effect:major bleeding events",
  "Side Effect:major but not minor hemorrhage",
  "Side Effect:major cardiovascular events",
  "Side Effect:major cardiovascular events (MACE)",
  "Side Effect:major cardiovascular events (MACE) at 1 year",
  "Side Effect:major cardiovascular events (MACE) rate",
  "Side Effect:major cardiovascular events or occurrence of stent thrombosis",
  "Side Effect:major hemorrhage",
  "Side Effect:major or minor hemorrhage",
  "Side Effect:mean cumulative doses of isoniazid before the development of abnormal liver-function tests (ALFTs)",
  "Side Effect:mean cumulative doses of isoniazid before the development of antituberculosis drug-induced hepatotoxicity (ATDIH)",
  "Side Effect:methotrexate-induced nodulosis",
  "Side Effect:micronucleated binucleated cells",
  "Side Effect:minor drug reactions",
  "Side Effect:moderate anemia",
  "Side Effect:mortality",
  "Side Effect:motor fluctuations",
  "Side Effect:motor side effects",
  "Side Effect:mucositis",
  "Side Effect:muscle effects",
  "Side Effect:musculoskeletal toxicity",
  "Side Effect:myalgia",
  "Side Effect:myelosuppression",
  "Side Effect:myelosuppression or any other side effect",
  "Side Effect:myelotoxicity",
  "Side Effect:myocardial infarction (MI) or composite outcome of non-fatal MI",
  "Side Effect:myopathy",
  "Side Effect:narcosis",
  "Side Effect:nausea",
  "Side Effect:nausea and vomiting",
  "Side Effect:nausea/vomiting",
  "Side Effect:necessity to reduce irinotecan dosage",
  "Side Effect:nephrotoxicity",
  "Side Effect:nephrotoxicity (geometirc changes in serum creatinine level)",
  "Side Effect:nephrotoxicity grades 1-4",
  "Side Effect:neurological ADR",
  "Side Effect:neurological adverse reactions",
  "Side Effect:neurological events",
  "Side Effect:neuropathy",
  "Side Effect:neuropsychiatric adverse events",
  "Side Effect:neurotoxicity",
  "Side Effect:neutropenia",
  "Side Effect:neutropenia and infections",
  "Side Effect:neutropenia grade 3-4",
  "Side Effect:new-onset diabetes mellitus",
  "Side Effect:nodular regenerative hyperplasia",
  "Side Effect:non-HDL cholesterol",
  "Side Effect:non-hematological toxicity",
  "Side Effect:number of weeks in which maintenance therapy had to be skipped",
  "Side Effect:obesity",
  "Side Effect:obsessive-compulsive symptoms",
  "Side Effect:oedema",
  "Side Effect:onset of toxicity",
  "Side Effect:opioid related adverse events ( immediate pain relief from codeine but stopped taking it due to dizziness and constipation)",
  "Side Effect:opioid withdrawal symptoms",
  "Side Effect:oral mucositis",
  "Side Effect:osteonecrosis",
  "Side Effect:over anti-coagulation",
  "Side Effect:over-anticoagulation",
  "Side Effect:overall ADRs",
  "Side Effect:overall gastrointestinal toxicity",
  "Side Effect:overanticoagulation",
  "Side Effect:pancreatitis",
  "Side Effect:paraesthesias",
  "Side Effect:periorbital edema",
  "Side Effect:peripheral neuropathy",
  "Side Effect:phenytoin toxicity",
  "Side Effect:plasma exposure",
  "Side Effect:plasma insulin levels",
  "Side Effect:plasma levels",
  "Side Effect:plasma total homocysteine concentrations",
  "Side Effect:plasma triglycerides",
  "Side Effect:platelet reactivity",
  "Side Effect:postoperative atrial fibrillation",
  "Side Effect:primary clinical endpoint of death due to cardiovascular causes",
  "Side Effect:prolactin concentrations",
  "Side Effect:prolactin level",
  "Side Effect:prolonged QTc",
  "Side Effect:pulmonary toxicity",
  "Side Effect:red blood cell transfusions",
  "Side Effect:reflex",
  "Side Effect:relapse of psychosis",
  "Side Effect:renal function (lower creatinine clearance) at 3 months of follow-up",
  "Side Effect:renal proximal tubulopathy",
  "Side Effect:repeat revascularization",
  "Side Effect:requirement for earlier dose reduction of ribavirin",
  "Side Effect:requiring a blood transfusion",
  "Side Effect:respiratory depression",
  "Side Effect:sadness",
  "Side Effect:scores of postoperative nausea and vomiting",
  "Side Effect:second malignancy",
  "Side Effect:sedation",
  "Side Effect:seizures",
  "Side Effect:sensitivity to aspirin",
  "Side Effect:sensoric neuropathy or neutropenia",
  "Side Effect:sensory peripheral neuropathy",
  "Side Effect:serious adverse events",
  "Side Effect:serious hypersensitivity",
  "Side Effect:serious infections",
  "Side Effect:serum bicarbonate levels",
  "Side Effect:serum creatine kinase levels (increased risk of myalgia and greater degree of muscle damage)",
  "Side Effect:serum potassium",
  "Side Effect:severe adverse effects",
  "Side Effect:severe adverse reactions",
  "Side Effect:severe and prolonged pancytopenia",
  "Side Effect:severe cardiotoxicity (refractory cardiac arrest)",
  "Side Effect:severe cutaneous adverse drug reactions",
  "Side Effect:severe emesis",
  "Side Effect:severe hearing impairment",
  "Side Effect:severe hematological toxicity",
  "Side Effect:severe hemolysis",
  "Side Effect:severe hemolytic anemia",
  "Side Effect:severe leukopenia",
  "Side Effect:severe myelosuppression",
  "Side Effect:severe neutropenia",
  "Side Effect:severe pancytopenia",
  "Side Effect:severe statin myopathy and unknown myopathy",
  "Side Effect:severe/ unsafe hemoglobin decreases",
  "Side Effect:sexsual dysfunction",
  "Side Effect:sexual dysfunction",
  "Side Effect:sexual side-effects",
  "Side Effect:side effects",
  "Side Effect:sleep disturbances",
  "Side Effect:sleepiness",
  "Side Effect:somnolence",
  "Side Effect:specific adverse events",
  "Side Effect:speed of platelet recovery",
  "Side Effect:statin intolerance",
  "Side Effect:statin-related myopathy",
  "Side Effect:stent thrombosis",
  "Side Effect:stent thrombosis (ST)",
  "Side Effect:stent thrombosis (ST) after 1 year",
  "Side Effect:stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI)",
  "Side Effect:suicidal ideation",
  "Side Effect:suicide",
  "Side Effect:systolic blood pressure and increased risk of developing grade 3 hypertension",
  "Side Effect:tachycardia and agitation",
  "Side Effect:the highest mean increased QT",
  "Side Effect:the lowest mean increased QT",
  "Side Effect:time above therapeutic range",
  "Side Effect:time below therapeutic range",
  "Side Effect:time to anemia in patients undergoing living or deceased donor kidney transplant",
  "Side Effect:time to discontinuation or dose reduction",
  "Side Effect:total cholesterol",
  "Side Effect:total hemorrhage and major hemorrhage",
  "Side Effect:toxicity",
  "Side Effect:toxicity-related treatment failure",
  "Side Effect:treatment interruptions",
  "Side Effect:treatment-emergent suicidal ideation",
  "Side Effect:treatment-emergent suicidality",
  "Side Effect:tremor and rigidity",
  "Side Effect:triglyceride levels",
  "Side Effect:triglycerides",
  "Side Effect:triglycerides in postmenopausal woman",
  "Side Effect:unsafe hemoglobin decreases or requirement for a blood transfusion",
  "Side Effect:urinary potassium excretion",
  "Side Effect:veno-occlusive disease of the liver",
  "Side Effect:venoocclusive disease of the liver",
  "Side Effect:venous thrombosis events during the 6-year follow up in patients with mechanical heart valve replacement",
  "Side Effect:violent psychosis",
  "Side Effect:vomiting",
  "Side Effect:weight gain",
  "Side Effect:withdrawal",
  "Side Effect:withdrawal effects",
  "Spontaneous",
  "Squamous Cell",
  "Subdural",
  "Toxic",
  "Toxic or Stevens-Johnson Syndrome",
  "Toxicity",
  "Type 2",
  "all cause death and stent thrombosis",
  "and 200 mg/day",
  "and ADP-induced P-selectin expression",
  "and a smaller oseltamivir carboxylate-to-oseltamivir AUC ratio",
  "and epinephrine",
  "and fewer swollen joints",
  "and happiness",
  "and high-density lipoprotein (HDL) cholesterol",
  "and its metabolites S-DCIT and S-DDCIT",
  "and lower AUC",
  "and mean arterial pressure in PMs than in non-PMs.",
  "and preference",
  "and sensitivity to the induction chemotherapy treatment",
  "apnea and brain injury",
  "but is not a significant factor in influencing the time to reach stable dose in Korean patients with MHVR",
  "changes in lymphocyte subsets over time",
  "collagen",
  "consumption",
  "decreased dosing compliance and lower plasma levels at day 28",
  "defined primarily through muscle symptomatology",
  "diarrhea and dizziness",
  "diastolic blood pressure",
  "dizziness",
  "elimination half-life",
  "end-of-treatment and sustained virological response) in HCV-5 infected chronic hepatitis C patients",
  "end-systolic and end-diastolic volume",
  "faster thrombin-mediated fibrinogen proteolysis and factor XIII activation (P=0.012)",
  "febrile neutropenia or hand-foot syndrome",
  "frequency of bruising and mild spontaneous bleeding events",
  "heaviness of smoking index and Fagerstrom test for nicotine dependence",
  "higher half-life and lower flurbiprofen clearance",
  "however this can be eliminated",
  "in a gene-dose-dependent manner",
  "independent of CYP2C9*2 and CYP2C9*3.",
  "indicating a longer period for falling asleep",
  "less patient-assessed difficulty with physical tasks",
  "lipid or lipoprotein levels",
  "longer elimination half-lives )",
  "lower Cmax of oseltamivir carboxylate",
  "major and minor hemorrhage as well as over anticoagulation",
  "may require a higher dose (INR never reached)",
  "mirtazapine S(+)/R(-) ratios and S(+)-N-desmethylmirtazapine",
  "myocardial infarction",
  "myocardial infarction or stroke",
  "nausea",
  "ng/ml/mg/kg/day) ratio during the first month after transplantation",
  "non fatal myocardial infarction and stent thrombosis) up to 12 months' follow up",
  "non-fatal MI or stent thrombosis",
  "nonfatal myocardial infarction or nonfatal stroke)",
  "nor did it affect the risk of developing oedema",
  "omeprazole sulfone",
  "optimal cytoreduction",
  "or overall survival",
  "or plasma trough ritonavir concentrations",
  "or stroke",
  "orthostatic hypotension",
  "peg-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy)",
  "plasma concentrations or nausea",
  "plasma half-life and steady-state plasma concentrations of paroxetine",
  "progression-free survival",
  "pupillary",
  "revascularization or death",
  "sedation",
  "stent thrombosis) in Korean patients after PCI",
  "stimulation",
  "stroke",
  "tiredness and cognitive function)",
  "triglycerides",
  "triglycerides or CRP to pravastatin",
  "vasodilator-stimulated phosphoprotein phosphorylation index",
  "which affects blood clotting at the site of microvascular injury in healthy subjects",
  "who reported a stressful life event",
  "with increase of AUC(0-infinity) and reduction of clearance"
]